ID
DB00244|APRD01098|DB05376|
名称
Mesalazine
描述
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022]. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent [A174019]. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules [A174019]. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained [A174019, A174022].
cas号
89-57-6
唯一标识码
4Q81I59GXC
状态
solid
一般参考文献
Mayberry J: The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis. 2013 Dec;22(4):375-7.
Stolfi C, De Simone V, Pallone F, Monteleone G: Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci. 2013 Sep 3;14(9):17972-85. doi: 10.3390/ijms140917972.

Electronic Medicines Compendium: Asacol (mesalazine) 400mg MR Tablets Monograph
https://www.medicines.org.uk/emc/product/2217/smpc
Electronic Medicines Compendium: Pentasa (Mesalazine) Sachet 2g Monograph
https://www.medicines.org.uk/emc/product/6309/smpc
NIH Toxnet: Mesalazine Profile
https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7512
Pentasa (Mesalazine) FDA Label
//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/001/original/020049s025lbl.pdf?1548091158
F3001Pentasa (Mesalazine) FDA Label//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/001/original/020049s025lbl.pdf?1548091158
approved,
指示
Mesalazine is indicated for the induction of remission in patients with active or mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis [FDA Label], [L5101]. Prescribing information for mesalazine in the UK also indicates the medication for the maintenance of remission of Crohn's ileo-colitis [L5101].
药效学
Mesalazine is one of the two components of sulphasalazine, the other being sulphapyridine. It is the latter which is responsible for the majority of the side effects associated with sulphasalazine therapy whilst mesalazine is known to be the active moiety in the treatment of ulcerative colitis [L5101]. The pharmacodynamic actions of mesalazine occur in the colonic/rectal mucosae local to the delivery of drug from mesalazine tablets into the lumen [FDA Label]. There is information suggesting that the severity of colonic inflammation in ulcerative colitis patients treated with mesalazine is inversely correlated with mucosal concentrations of mesalazine [FDA Label]. Plasma concentrations representing systemically absorbed mesalazine are not believed to contribute extensively to efficacy [FDA Label].
作用机制
Although the mechanism of action of mesalazine is not fully understood, it is believed to possess a topical anti-inflammatory effect on colonic epithelial cells [FDA Label]. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon [FDA Label]. Furthermore, mesalazine also has the potential to inhibit the activation of Nuclear Factor kappa B (NKkB) and consequently the production of key of pro-inflammatory cytokines [FDA Label]. It has been proposed that reduced expression of PPAR gamma nuclear receptors (gamma form of peroxisome proliferator-activated receptors) may be implicated in ulcerative colitis [FDA Label]. There is evidence that mesalazine produces pharmacodynamic effects through direct activation of PPAR gamma receptors in the colonic/rectal epithelium as well [FDA Label]. Moreover, since increased leukocyte migration, abnormal cytokine production, increased production of arachidonic acid metabolites, particularly leukotriene B4, and increased free radical formation in the inflamed intestinal tissue are all present in patients with inflammatory bowel disease it is also believed that mesalazine has in-vitro and in-vivo pharmacological effects that inhibit leukocyte chemotaxis, decrease cytokine and leukotriene production and scavenge for free radicals [L5107].
毒性
Oral, mouse: LD50 = 3370 mg/kg; Oral, rat: LD50 = 2800 mg/kg; Skin, rabbit: LD50 = >5 gm/kg [MSDS]. There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalazine absorption from the colon is limited. Although there is little to no clinical experience with mesalazine overdosage [FDA Label]. Mesalazine is an aminosalicylate, and symptoms of salicylate toxicity may be possible, such as tinnitus, vertigo, headache, confusion, drowsiness, sweating, hyperventilation, vomiting, and diarrhea [FDA Label]. Severe intoxication with salicylates can lead to disruption of electrolyte balance and blood-pH, hyperthermia, and dehydration [FDA Label].
代谢
The primary metabolite of mesalazine (5-aminosalicylic acid) is predominantly N-acetyl-5-aminosalicylic acid (Ac-5-ASA) [FDA Label]. This metabolite is generated via N-acetyltransferase (NAT) activity in the liver and intestinal mucosa cells, largely by NAT-1, in particular [FDA Label].
吸收
Depending on the formulation administered, prescribing information for orally administered delayed-released tablets of 2.4g or 4.8g of mesalazine given once daily for 14 days to healthy volunteers was to found to be about 21% to 22% of the administered dose [FDA Label] while prescribing information for an orally administered controlled-release capsule formulation suggests 20% to 30% of the mesalazine in the formulation is absorbed [F3001]. In contrast, when mesalamine is administered orally as an unformulated 1-g aqueous suspension, mesalazine is approximately 80% absorbed [F3001].
半衰期
The apparent elimination half-life documented for oral delayed-release mesalazine tablets is 7 to 12 hours [L5122]. The elimination half-life recorded for the active N-acetyl-5-aminosalicylic acid metabolite generated from the administration of oral delayed-release mesalazine tablets is 12 to 23 hours [L5122].
分类
description:This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
direct-parent:Aminobenzoic acids
kingdom:Organic compounds
superclass:Benzenoids
class:Benzene and substituted derivatives
subclass:Benzoic acids and derivatives
alternative-parent:1-hydroxy-2-unsubstituted benzenoids
alternative-parent:Amino acids
alternative-parent:Aniline and substituted anilines
alternative-parent:Benzoic acids
alternative-parent:Benzoyl derivatives
alternative-parent:Carboxylic acids
alternative-parent:Hydrocarbon derivatives
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Organic oxides
alternative-parent:Organooxygen compounds
alternative-parent:Organopnictogen compounds
alternative-parent:Primary amines
alternative-parent:Salicylic acids
alternative-parent:Vinylogous acids
alternative-parent:p-Aminophenols
substituent:1-hydroxy-2-unsubstituted benzenoid
substituent:Amine
substituent:Amino acid
substituent:Amino acid or derivatives
substituent:Aminobenzoic acid
substituent:Aminophenol
substituent:Aniline or substituted anilines
substituent:Aromatic homomonocyclic compound
substituent:Benzoic acid
substituent:Benzoyl
substituent:Carboxylic acid
substituent:Carboxylic acid derivative
substituent:Hydrocarbon derivative
substituent:Hydroxybenzoic acid
substituent:Monocarboxylic acid or derivatives
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:P-aminophenol
substituent:Phenol
substituent:Primary amine
substituent:Salicylic acid
substituent:Salicylic acid or derivatives
substituent:Vinylogous acid
消除途径
Elimination of mesalazine is mainly via the renal route following metabolism to N-acetyl-5-aminosalicylic acid (acetylation) [FDA Label]. However, there is also limited excretion of the parent mesalazine drug in the urine [FDA Label]. After the oral administration of the extended-release formulation of mesalazine, of the approximately 21% to 22% of the drug absorbed, less than 8% of the dose was excreted unchanged in the urine after 24 hours, compared with greater than 13% for N-acetyl-5-aminosalicylic acid [FDA Label]. When given the controlled-release formulation, about 130 mg free mesalazine was recovered in the feces following a single 1-g dose, which was comparable to the 140 mg of mesalazine recovered from the molar equivalent sulfasalazine tablet dose of 2.5 g F3001]. Elimination of free mesalazine and salicylates in feces increased proportionately with the dose given. N-acetylmesalazine was the primary compound excreted in the urine (19% to 30%) following the controlled-release dosing [F3001].
种类
Agents causing hyperkalemia

Agents that produce hypertension

Aminosalicylate

Aminosalicylic Acids
D000636
Analgesics
D000700
Analgesics, Non-Narcotic
D018712
Anti-Inflammatory Agents
D000893
Anti-Inflammatory Agents, Non-Steroidal
D000894
Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)

Benzene Derivatives
D001555
Hydroxybenzoates
D062385
Intestinal Antiinflammatory Agents

Nephrotoxic agents

Non COX-2 selective NSAIDS

Phenols
D010636
Salicylates
D012459
盐类
蛋白质结合
Mesalazine is approximately 43% bound to plasma proteins [FDA Label], [L5122].
清除
The mean (SD) renal clearance in L/h for mesalazine following the single dose administration of mesalazine delayed-release tablets 4.8g under fasting conditions to young and elderly subjects was documented as 2.05 (1.33) in young subjects aged 18 to 35 years old, 2.04 (1.16) in elderly subjects aged 65 to 75 years old, and 2.13 (1.20) in elderly subjects older than 75 years [FDA Label].
同义词
language:english; code:; name;3-carboxy-4-hydroxyaniline
language:english; code:; name;5-aminosalicylic acid
language:english; code:; name;5-ASA
language:english; code:; name;m-Aminosalicylic acid
language:english; code:usan; name;Mesalamine
language:spanish; code:inn; name;Mesalazina
language:french; code:inn; name;Mésalazine
language:english; code:inn; name;Mesalazine
language:latin; code:inn; name;Mesalazinum
language:german; code:; name;p-Aminosalicylsaeure
国际品牌
AsacolitinClaversalFisalamineIialdaLixacol
配送量
The apparent volume of distribution (Vd) of the drug in adults is approximately 0.2 L/kg [L5122].
产品
name:5-asa
labeller:Sanis Health Inc
ndc-id:
ndc-product-code:
dpd-id:02351463
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-02
ended-marketing-on:2012-08-03
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apriso
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-6150
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-08-18
ended-marketing-on:
dosage-form:Capsule, extended release
strength:375 mg/1
route:Oral
fda-application-number:NDA022301
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Apriso
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:43353-884
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:375 mg/1
route:Oral
fda-application-number:NDA022301
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Apriso
labeller:Salix Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:65649-103
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:375 mg/1
route:Oral
fda-application-number:NDA022301
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:State of Florida DOH Central Pharmacy
ndc-id:
ndc-product-code:53808-0205
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-01
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Warner Chilcott
ndc-id:
ndc-product-code:0149-0752
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-04-01
ended-marketing-on:2011-11-17
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2515
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-05-10
ended-marketing-on:2011-06-30
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:State of Florida DOH Central Pharmacy
ndc-id:
ndc-product-code:53808-0823
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-01-01
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-568
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-01-23
ended-marketing-on:2012-02-29
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-494
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-08-10
ended-marketing-on:2012-02-16
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:49999-969
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-23
ended-marketing-on:2013-03-20
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-678
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-03-09
ended-marketing-on:2016-11-28
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Allergan
ndc-id:
ndc-product-code:0430-0752
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-04-01
ended-marketing-on:2015-06-30
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:49349-951
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-10-06
ended-marketing-on:2016-10-06
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0111
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-23
ended-marketing-on:2014-03-31
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-8607
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-04-01
ended-marketing-on:2015-05-31
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Allergan, Inc.
ndc-id:
ndc-product-code:0023-0752
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-04-01
ended-marketing-on:2015-06-30
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-2305
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-04-01
ended-marketing-on:2012-12-31
dosage-form:Tablet, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA019651
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol
labeller:Allergan
ndc-id:
ndc-product-code:
dpd-id:01997580
ema-product-code:
ema-ma-number:
started-marketing-on:1993-12-31
ended-marketing-on:2020-07-17
dosage-form:Tablet, delayed release
strength:400 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Asacol 800
labeller:Allergan
ndc-id:
ndc-product-code:
dpd-id:02267217
ema-product-code:
ema-ma-number:
started-marketing-on:2005-06-13
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Asacol HD
labeller:Warner Chilcott
ndc-id:
ndc-product-code:0149-0783
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-05-28
ended-marketing-on:2011-08-23
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol Hd
labeller:Allergan, Inc.
ndc-id:
ndc-product-code:0430-0783
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-05-28
ended-marketing-on:2019-03-31
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Asacol HD
labeller:Allergan, Inc.
ndc-id:
ndc-product-code:0023-5901
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-05-28
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Canasa
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-6147
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-08-18
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:NDA021252
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Canasa
labeller:Allergan, Inc.
ndc-id:
ndc-product-code:58914-501
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-01-05
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:NDA021252
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Canasa
labeller:McKesson Corporation dba RX Pak
ndc-id:
ndc-product-code:65084-474
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-01-05
ended-marketing-on:2019-09-01
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:NDA021252
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Delzicol
labeller:Carilion Materials Management
ndc-id:
ndc-product-code:68151-5652
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-01
ended-marketing-on:
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA204412
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Delzicol
labeller:Warner Chilcott
ndc-id:
ndc-product-code:0430-0854
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-31
ended-marketing-on:2016-03-31
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA204412
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Delzicol
labeller:Allergan
ndc-id:
ndc-product-code:0430-0753
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-01
ended-marketing-on:2018-05-31
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA204412
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Delzicol
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3002
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-16
ended-marketing-on:
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA204412
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Delzicol
labeller:Allergan, Inc.
ndc-id:
ndc-product-code:0023-5853
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-16
ended-marketing-on:
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA204412
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lialda
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0142
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-12-06
ended-marketing-on:2019-03-31
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:NDA022000
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lialda
labeller:Takeda Pharmaceuticals America, Inc.
ndc-id:
ndc-product-code:54092-476
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-16
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:NDA022000
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lialda
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-0476
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-04-03
ended-marketing-on:2017-05-24
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:NDA022000
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Teva
ndc-id:
ndc-product-code:0093-6888
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-09-30
ended-marketing-on:2013-01-31
dosage-form:Suspension
strength:4 g/60mL
route:Rectal
fda-application-number:ANDA076841
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Zydus Pharmaceuticals Usa, Inc.
ndc-id:
ndc-product-code:68382-484
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-08-01
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:60687-264
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-11-18
ended-marketing-on:2019-02-28
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Franklin Pharmaceutical LLC
ndc-id:
ndc-product-code:50532-066
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-04-01
ended-marketing-on:2018-01-01
dosage-form:Suspension
strength:4 g/60mL
route:Rectal
fda-application-number:NDA019618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Zydus Pharmaceuticals Usa, Inc.
ndc-id:
ndc-product-code:68382-649
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-08-01
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Greenstone LLC
ndc-id:
ndc-product-code:59762-0118
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-12-07
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:NDA021252
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-9230
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-12-17
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA204354
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:American Health Packaging
ndc-id:
ndc-product-code:60687-347
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-12-21
ended-marketing-on:2020-01-31
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Letco Medical
ndc-id:
ndc-product-code:62991-2705
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-30
ended-marketing-on:
dosage-form:Powder
strength:1 g/1g
route:Not applicable
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Mesalamine
labeller:Rising Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:64980-282
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-05
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA207448
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:American Health Packaging
ndc-id:
ndc-product-code:60687-397
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-09-01
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA091640
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:70771-1071
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-06-19
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA091640
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:68382-711
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-06-19
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA091640
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:63304-175
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-01
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA211858
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:AvKARE, Inc
ndc-id:
ndc-product-code:42291-563
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-08-26
ended-marketing-on:
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:ANDA207873
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:AvKARE, Inc
ndc-id:
ndc-product-code:42291-564
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-09-18
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA203817
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Northstar Rx Llc.
ndc-id:
ndc-product-code:16714-830
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-25
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA091640
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Shire US Manufacturing Inc.
ndc-id:
ndc-product-code:54092-100
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-08-29
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:NDA022000
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Perrigo New York Inc
ndc-id:
ndc-product-code:45802-098
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-11
ended-marketing-on:
dosage-form:Enema
strength:4 g/60mL
route:Rectal
fda-application-number:ANDA076751
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:ANI Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:62559-420
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-13
ended-marketing-on:
dosage-form:Enema
strength:4 g/60mL
route:Rectal
fda-application-number:NDA019618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-7401
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-12-14
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA203574
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-1375
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-11-26
ended-marketing-on:
dosage-form:Capsule, extended release
strength:0.375 g/1
route:Oral
fda-application-number:ANDA207271
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Oceanside Pharmaceuticals
ndc-id:
ndc-product-code:68682-113
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:375 mg/1
route:Oral
fda-application-number:NDA022301
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:68382-435
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-08-02
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:ANDA203286
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:70771-1110
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-08-02
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:ANDA203286
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Amneal Pharmaceuticals NY LLC
ndc-id:
ndc-product-code:69238-1274
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-08
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA210509
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:American Health Packaging
ndc-id:
ndc-product-code:60687-408
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-03
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:ANDA203286
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3497
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-08-01
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:NDA021830
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-7088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-11-01
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA202065
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:70771-1513
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-14
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA208953
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:70710-1302
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-14
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA208953
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Teva Pharmaceuticals USA, Inc.
ndc-id:
ndc-product-code:0093-5907
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-09
ended-marketing-on:
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:ANDA207873
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Greenstone LLC
ndc-id:
ndc-product-code:59762-0117
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-10
ended-marketing-on:
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:NDA204412
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Camber Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:31722-005
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-19
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA213377
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Perrigo New York Inc
ndc-id:
ndc-product-code:45802-929
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-08-02
ended-marketing-on:
dosage-form:
strength:4 g/60mL
route:Rectal
fda-application-number:ANDA076751
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Perrigo New York Inc
ndc-id:
ndc-product-code:45802-923
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-01
ended-marketing-on:
dosage-form:
strength:4 g/60mL
route:Rectal
fda-application-number:ANDA076751
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Lupin Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:70748-214
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-05-18
ended-marketing-on:
dosage-form:Capsule, extended release
strength:375 mg/1
route:Oral
fda-application-number:NDA022301
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0591-2245
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-03-26
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:1.2 g/1
route:Oral
fda-application-number:ANDA203817
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Lupin Pharmaceuticals,Inc.
ndc-id:
ndc-product-code:43386-510
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-16
ended-marketing-on:2018-06-30
dosage-form:Enema
strength:4 g/60mL
route:Rectal
fda-application-number:NDA019618
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Prasco Laboratories
ndc-id:
ndc-product-code:66993-410
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-05-10
ended-marketing-on:1993-05-10
dosage-form:Capsule
strength:250 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Prasco Laboratories
ndc-id:
ndc-product-code:66993-411
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-07-08
ended-marketing-on:2004-07-08
dosage-form:Capsule
strength:500 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:American Health Packaging
ndc-id:
ndc-product-code:60687-556
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-01
ended-marketing-on:
dosage-form:Capsule, delayed release
strength:400 mg/1
route:Oral
fda-application-number:ANDA207873
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Teva Pharmaceuticals USA, Inc.-
ndc-id:
ndc-product-code:0093-9224
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-26
ended-marketing-on:
dosage-form:Capsule, extended release
strength:375 mg/1
route:Oral
fda-application-number:NDA022301
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6832
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-08-02
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:ANDA203286
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesalamine Rectal
labeller:Amring Pharmaceuticals Inc.
ndc-id:
ndc-product-code:69918-560
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-24
ended-marketing-on:
dosage-form:Suppository
strength:1000 mg/1
route:Rectal
fda-application-number:ANDA208362
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mesasal
labeller:Glaxosmithkline Inc
ndc-id:
ndc-product-code:
dpd-id:01914030
ema-product-code:
ema-ma-number:
started-marketing-on:1992-12-31
ended-marketing-on:2017-03-23
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mezavant
labeller:Shire Pharma Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02297558
ema-product-code:
ema-ma-number:
started-marketing-on:2007-07-27
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mezera
labeller:Avir Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02474018
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-13
ended-marketing-on:
dosage-form:Suppository
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mezera
labeller:Avir Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02474026
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-13
ended-marketing-on:
dosage-form:Kit
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ntp-5-aminosalicylic Acid
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02348063
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pendo-5 Asa
labeller:Pendopharm Division Of Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:02265257
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pentasa
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5302
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-05-20
ended-marketing-on:2012-06-30
dosage-form:Capsule
strength:500 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentasa
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-561
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-10-04
ended-marketing-on:2012-10-04
dosage-form:Capsule
strength:500 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentasa
labeller:Carilion Materials Management
ndc-id:
ndc-product-code:68151-4769
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-05-10
ended-marketing-on:
dosage-form:Capsule
strength:250 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentasa
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-0189
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-04-27
ended-marketing-on:
dosage-form:Capsule
strength:250 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentasa
labeller:Takeda Pharmaceuticals America, Inc.
ndc-id:
ndc-product-code:54092-189
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-05-10
ended-marketing-on:
dosage-form:Capsule
strength:250 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentasa
labeller:Takeda Pharmaceuticals America, Inc.
ndc-id:
ndc-product-code:54092-191
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-07-08
ended-marketing-on:
dosage-form:Capsule
strength:500 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentasa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5952
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-05-10
ended-marketing-on:2013-10-31
dosage-form:Capsule
strength:250 mg/1
route:Oral
fda-application-number:NDA020049
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentasa
labeller:Ferring Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02099683
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Tablet, extended release
strength:500 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pentasa
labeller:Ferring Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02153564
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Suppository
strength:1 g
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pentasa
labeller:Ferring Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02153556
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Suspension
strength:4 g
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pentasa
labeller:Ferring Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02153521
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Suspension
strength:1 g
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pentasa
labeller:Ferring Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02399466
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:1 g
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pentasa Enema 2g/100ml
labeller:Ferring Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02153548
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:2004-08-05
dosage-form:Enema; Liquid
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pentasa Extended-release Tablets 250mg
labeller:Ferring Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02099675
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:2004-08-05
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Rowasa
labeller:Alaven Pharmaceutical
ndc-id:
ndc-product-code:68220-066
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-01-31
ended-marketing-on:2017-09-30
dosage-form:Enema
strength:4 g/60mL
route:Rectal
fda-application-number:NDA019618
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Rowasa
labeller:MEDA Pharmaceuticals
ndc-id:
ndc-product-code:0037-0066
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-29
ended-marketing-on:
dosage-form:Suspension
strength:4 g/60mL
route:Rectal
fda-application-number:NDA019618
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Salofalk
labeller:Aptalis Pharma Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02112760
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Suppository
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Salofalk
labeller:Aptalis Pharma Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02112787
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Salofalk
labeller:Aptalis Pharma Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02112809
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Suspension
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Salofalk
labeller:Aptalis Pharma Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02112795
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Suspension
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Salofalk
labeller:Aptalis Pharma Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02242146
ema-product-code:
ema-ma-number:
started-marketing-on:2000-06-01
ended-marketing-on:
dosage-form:Suppository
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Salofalk (r) 5-asa Enteric Coated Tab- 250mg
labeller:Axcan Pharma
ndc-id:
ndc-product-code:
dpd-id:02112779
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:1998-08-03
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Salofalk (r) 5-asa Suppositories - 250mg
labeller:Axcan Pharma
ndc-id:
ndc-product-code:
dpd-id:02112752
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:2006-09-12
dosage-form:Suppository
strength:
route:Rectal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:sF Rowasa
labeller:Alaven Pharmaceutical
ndc-id:
ndc-product-code:68220-022
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-01
ended-marketing-on:2016-10-30
dosage-form:Suspension
strength:4 g/60mL
route:Rectal
fda-application-number:NDA019618
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:sfRowasa Sulfite-Free Formulation
labeller:MEDA Pharmaceuticals
ndc-id:
ndc-product-code:0037-0022
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-29
ended-marketing-on:
dosage-form:Suspension
strength:4 g/60mL
route:Rectal
fda-application-number:NDA019618
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Teva-5 Asa
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02171929
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Zaldyon
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:70710-1543
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-17
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:ANDA203286
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Zaldyon
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:70771-1353
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-17
ended-marketing-on:
dosage-form:Tablet, delayed release
strength:800 mg/1
route:Oral
fda-application-number:ANDA203286
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
混合物
name:Canasa
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Apriso
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Asacol HD
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Rowasa
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Delzicol
ingredients:Mesalazine
name:sF Rowasa
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Delzicol
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Delzicol
ingredients:Mesalazine
name:Apriso
ingredients:Mesalazine
name:Rowasa
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Canasa
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Lialda
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Lialda
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Zaldyon
ingredients:Mesalazine
name:Zaldyon
ingredients:Mesalazine
name:Mesalamine Rectal
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:sfRowasa Sulfite-Free Formulation
ingredients:Mesalazine
name:Delzicol
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Apriso
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Delzicol
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Canasa
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Asacol Hd
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Lialda
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Asacol HD
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:Mesalamine
ingredients:Mesalazine
name:5-asa
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Salofalk
ingredients:Mesalazine
name:Salofalk
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Salofalk
ingredients:Mesalazine
name:Salofalk
ingredients:Mesalazine
name:Teva-5 Asa
ingredients:Mesalazine
name:Salofalk
ingredients:Mesalazine
name:Asacol 800
ingredients:Mesalazine
name:Mezavant
ingredients:Mesalazine
name:Pentasa
ingredients:Mesalazine
name:Mesasal
ingredients:Mesalazine
name:Pentasa Extended-release Tablets 250mg
ingredients:Mesalazine
name:Salofalk (r) 5-asa Suppositories - 250mg
ingredients:Mesalazine
name:Pentasa Enema 2g/100ml
ingredients:Mesalazine
name:Salofalk (r) 5-asa Enteric Coated Tab- 250mg
ingredients:Mesalazine
name:Ntp-5-aminosalicylic Acid
ingredients:Mesalazine
name:Pendo-5 Asa
ingredients:Mesalazine
name:Mezera
ingredients:Mesalazine
name:Mezera
ingredients:Mesalazine
name:Asacol
ingredients:Mesalazine
包装者
name:Alaven Pharmaceutical
url:http://www.alavenpharm.com
name:Amerisource Health Services Corp.
url:http://www.amerisourcebergen.com
name:Anip Acquisition Co.
url:
name:Atlantic Biologicals Corporation
url:http://www.atlanticbiologicals.com
name:Axcan Pharma Inc.
url:http://www.axcan.com
name:Cardinal Health
url:http://www.cardinal.com
name:Comprehensive Consultant Services Inc.
url:
name:Cosmo SPA
url:
name:Dept Health Central Pharmacy
url:
name:Diversified Healthcare Services Inc.
url:http://www.dhscorp.com
name:Ferring Pharmaceuticals Inc.
url:http://www.ferring.com
name:Franklin Pharmaceutical LLC
url:
name:Gavis Pharmaceuticals LLC
url:http://www.gavispharma.com
name:Heartland Repack Services LLC
url:
name:Infar SA
url:
name:Letco Medical Inc.
url:http://www.letcomedical.com
name:Norwich Pharmaceuticals Inc.
url:http://www.norwichpharma.com
name:Paddock Labs
url:http://www.paddocklabs.com
name:PD-Rx Pharmaceuticals Inc.
url:http://www.pdrx.com
name:Perrigo Co.
url:http://www.perrigo.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Prasco Labs
url:http://www.prasco.com
name:Prepak Systems Inc.
url:http://www.prepaksys.com
name:Resource Optimization and Innovation LLC
url:
name:Salix Pharmaceuticals
url:http://www.salix.com
name:Sanofi-Aventis Inc.
url:http://www.sanofi-aventis.com
name:Shire Inc.
url:http://www.shire.com
name:Solvay Pharmaceuticals
url:http://global.abbottgrowth.com
name:Teva Pharmaceutical Industries Ltd.
url:http://www.tevapharm.com
name:Vangard Labs Inc.
url:
name:Warner Chilcott Co. Inc.
url:http://ir.wcrx.com
name:WC Pharmaceuticals
url:
name:Wellspring Pharmaceutical
url:http://www.wellspringpharm.com
生产者
generic:否; url:; name;Salix pharmaceuticals inc
generic:否; url:; name;Shire development inc
generic:是; url:; name;Perrigo israel pharmaceuticals ltd
generic:是; url:; name;Teva pharmaceuticals usa inc
generic:否; url:; name;Alaven pharmaceutical llc
generic:否; url:; name;Axcan pharma us inc
generic:否; url:; name;Warner chilcott pharmaceuticals inc
价格
Pentasa 250 mg capsule
1.07(单位:USD)
capsule
Asacol 800 800 mg Enteric-Coated Tablet
1.14(单位:USD)
tablet
Salofalk 500 mg Suppository
1.23(单位:USD)
suppository
Pentasa 1 g Suppository
1.8(单位:USD)
suppository
Salofalk 1000 mg Suppository
1.81(单位:USD)
suppository
Asacol ec 400 mg tablet
1.94(单位:USD)
tablet
Asacol 400 mg Enteric Coated Tabs
2.22(单位:USD)
tab
Pentasa 500 mg capsule
2.66(单位:USD)
capsule
Asacol hd dr 800 mg tablet
3.88(单位:USD)
tablet
Salofalk (2 g/60 g) 2 g/enm Enema
3.96(单位:USD)
enema
Pentasa (1 g/100Ml) 1 g/enm Enema
4.17(单位:USD)
enema
Pentasa (4 g/100 Ml) 4 g/enm Enema
5.02(单位:USD)
enema
Canasa 500 mg suppository
6.24(单位:USD)
suppository
Salofalk (4 g/60 g) 4 g/enm Enema
6.73(单位:USD)
enema
Canasa 1000 mg suppository
13.88(单位:USD)
suppository
Canasa 30 1000 mg Suppository Box
488.32(单位:USD)
box
Rowasa 4 gm/60 ml enema
0.41(单位:USD)
ml
Novo-5 Asa 400 mg Enteric-Coated Tablet
0.42(单位:USD)
tablet
Salofalk 500 mg Enteric-Coated Tablet
0.56(单位:USD)
tablet
Asacol 400 mg Enteric-Coated Tablet
0.59(单位:USD)
tablet
Pentasa 500 mg Sustained-Release Tablet
0.63(单位:USD)
tablet
Mesasal 500 mg Enteric-Coated Tablet
0.69(单位:USD)
tablet
受影响的生物体
Humans and other mammals
剂量
form:Capsule, extended release
route:Oral
strength:375 mg/1
form:Capsule, delayed release
route:Oral
strength:400 MG
form:Granule, for suspension
route:Rectal
strength:2 G
form:Suspension
route:Rectal
strength:2 G/50ML
form:Suspension
route:Rectal
strength:4 G/50ML
form:Tablet
route:Oral
strength:400 mg/1
form:Tablet, delayed release
route:Oral
strength:400 mg/1
form:Tablet, delayed release
route:Oral
strength:1600 MG
form:
route:Rectal
strength:4 g/100ml
form:Tablet, delayed release
route:Oral
strength:
form:Tablet, delayed release
route:Oral
strength:400 MG
form:Tablet, delayed release
route:Oral
strength:800 MG
form:Tablet, delayed release
route:Oral
strength:800 mg/1
form:Aerosol, foam
route:Rectal
strength:2 G
form:Aerosol, foam
route:Rectal
strength:4 G
form:Enema
route:Rectal
strength:2 G
form:Enema
route:Rectal
strength:4 G
form:Gel
route:Rectal
strength:500 MG
form:Granule, for suspension
route:Rectal
strength:1.5 G
form:Suppository
route:Rectal
strength:400 MG
form:Tablet
route:Oral
strength:400 MG
form:Tablet
route:Oral
strength:800 MG
form:Suppository
route:Rectal
strength:1000 mg/1
form:Suppository
route:Rectal
strength:0.5 g
form:Suspension
route:Rectal
strength:2 g
form:Suppository
route:Rectal
strength:250 MG
form:Suspension
route:Rectal
strength:4 G/60G
form:Tablet, film coated
route:Oral
strength:500 mg
form:Tablet, delayed release
route:Oral
strength:500 MG
form:Suppository
route:Rectal
strength:500 MG
form:Granule, delayed release
route:Oral
strength:1.5 G
form:Aerosol, foam
route:Rectal
strength:1 G
form:Capsule, delayed release
route:Oral
strength:400 mg/1
form:Tablet, delayed release
route:Oral
strength:1.2 g/1
form:Suspension
route:Rectal
strength:6.67 g
form:Tablet, coated
route:Oral
strength:500 mg
form:Solution
route:Rectal
strength:2 G
form:Solution
route:Rectal
strength:4 G
form:Granule, delayed release
route:Oral
strength:1500 mg
form:Granule, delayed release
route:Oral
strength:3000 mg
form:
route:Rectal
strength:4 g/60mL
form:Capsule, extended release
route:Oral
strength:0.375 g/1
form:Powder
route:Not applicable
strength:1 g/1g
form:Suspension
route:Rectal
strength:4 g/60mL
form:Aerosol, foam
route:Rectal
strength:
form:Gel
route:Rectal
strength:500 MG/5G
form:Powder
route:Rectal
strength:1.5 G
form:Capsule
route:Oral
strength:400 MG
form:Gel
route:Rectal
strength:2 G/60ML
form:Gel
route:Rectal
strength:4 G/60ML
form:Gel
route:Rectal
strength:10 %
form:Tablet, extended release
route:Oral
strength:1200 MG
form:Tablet, extended release
route:Oral
strength:
form:Suspension
route:Rectal
strength:7 g
form:Suspension
route:Rectal
strength:6667 mg
form:Tablet, coated
route:Oral
strength:505 mg
form:Tablet, delayed release
route:Oral
strength:1200 MG
form:Tablet, extended release
route:Oral
strength:1.2 g
form:Tablet, film coated, extended release
route:Oral
strength:1200 mg
form:Kit
route:Rectal
strength:
form:Suspension
route:Rectal
strength:4 G/100ML
form:Tablet
route:Oral
strength:1200 MG
form:Capsule
route:Oral
strength:250 mg/1
form:Capsule
route:Oral
strength:500 mg/1
form:Suspension
route:Rectal
strength:2 G/100ML
form:Tablet
route:Oral
strength:250 MG
form:Enema
route:Rectal
strength:1 g/100ml
form:Suspension
route:Rectal
strength:1 g/100ml
form:Granule, delayed release
route:Oral
strength:1 g
form:Tablet, extended release
route:Oral
strength:1 g
form:Suppository
route:Rectal
strength:1.000 MG
form:Suppository
route:Rectal
strength:1000 MG
form:Tablet, extended release
route:Oral
strength:1000 MG
form:Suspension
route:Rectal
strength:1000 MG
form:Suspension
route:Rectal
strength:
form:Tablet
route:Oral
strength:500 mg
form:Tablet, extended release
route:Oral
strength:500 MG
form:Enema
route:Rectal
strength:1 g
form:Enema; liquid
route:Rectal
strength:
form:Suspension
route:Rectal
strength:1 g/100 ml
form:Granule
route:Oral
strength:1 g
form:Tablet
route:Oral
strength:1 g
form:Granule
route:Oral
strength:2 g
form:Granule
route:Oral
strength:4 g
form:Granule, delayed release
route:Oral
strength:1000 MG
form:Granule, delayed release
route:Oral
strength:
form:Granule, delayed release
route:Oral
strength:4 G
form:Granule, delayed release
route:Oral
strength:2 G
form:Suspension
route:Rectal
strength:1 g
form:Granule
route:Oral
strength:2000 mg
form:Gel
route:Rectal
strength:2 G
form:Gel
route:Rectal
strength:4 G
form:Enema
route:Rectal
strength:4 g/60mL
form:Enema
route:Rectal
strength:4 G/60G
form:Granule, delayed release
route:Oral
strength:1.5 g/2.79g
form:Suppository
route:Rectal
strength:
form:Emulsion
route:Rectal
strength:1 g
form:Granule
route:Oral
strength:3000 mg
form:Suppository
route:Rectal
strength:1 G
form:Tablet, delayed release
route:Oral
strength:1 G
form:
route:Rectal
strength:1 g
form:Tablet, delayed release
route:Oral
strength:250 MG
form:Suspension
route:Rectal
strength:2 G/30ML
form:Suspension
route:Rectal
strength:4 g
form:
route:Rectal
strength:4 g/60g
form:Granule, delayed release
route:Oral
strength:3 G
form:Granule, delayed release
route:Oral
strength:500 MG
form:Granule
route:Oral
strength:1000 mg
form:Granule
route:Oral
strength:1500 mg
form:Granule
route:Oral
strength:500 mg
form:Tablet
route:Oral
strength:1600 MG
atc代码
Aminosalicylic acid and similar agents
INTESTINAL ANTIINFLAMMATORY AGENTS
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
ALIMENTARY TRACT AND METABOLISM
fda标签
//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00244.pdf?1547768602
化学品安全技术说明书
//s3-us-west-2.amazonaws.com/drugbank/msds/DB00244.pdf?1265922743
专利
number:5541170
country:United States
approved:1996-07-30
expires:2013-07-30
pediatric-extension:否
number:2444814
country:Canada
approved:2009-06-09
expires:2021-10-24
pediatric-extension:否
number:2111697
country:Canada
approved:2002-08-20
expires:2012-06-16
pediatric-extension:否
number:7645801
country:United States
approved:2010-01-12
expires:2027-07-24
pediatric-extension:否
number:6773720
country:United States
approved:2004-08-10
expires:2020-06-08
pediatric-extension:否
number:8436051
country:United States
approved:2013-05-07
expires:2028-06-06
pediatric-extension:否
number:8217083
country:United States
approved:2012-07-10
expires:2028-06-06
pediatric-extension:否
number:6893662
country:United States
approved:2005-05-17
expires:2021-11-15
pediatric-extension:否
number:8580302
country:United States
approved:2013-11-12
expires:2021-11-15
pediatric-extension:否
number:9089492
country:United States
approved:2015-07-28
expires:2021-11-15
pediatric-extension:否
number:8911778
country:United States
approved:2014-12-16
expires:2018-04-20
pediatric-extension:否
number:6551620
country:United States
approved:2003-04-22
expires:2018-04-20
pediatric-extension:否
number:8337886
country:United States
approved:2012-12-25
expires:2018-04-20
pediatric-extension:否
number:8865688
country:United States
approved:2014-10-21
expires:2030-05-01
pediatric-extension:否
number:8496965
country:United States
approved:2013-07-30
expires:2018-04-20
pediatric-extension:否
number:8940328
country:United States
approved:2015-01-27
expires:2018-04-20
pediatric-extension:否
number:8956647
country:United States
approved:2015-02-17
expires:2018-04-20
pediatric-extension:否
number:6649180
country:United States
approved:2003-11-18
expires:2020-04-13
pediatric-extension:否
食物相互作用
Take with or without food. The absorption is unaffected by food.
药物相互作用
DB00381
Mesalazine may decrease the antihypertensive activities of Amlodipine.
DB00191
The risk or severity of hypertension can be increased when Phentermine is combined with Mesalazine.
DB00211
The risk or severity of hypertension can be increased when Midodrine is combined with Mesalazine.
DB00216
The risk or severity of hypertension can be increased when Eletriptan is combined with Mesalazine.
DB00221
The risk or severity of hypertension can be increased when Isoetharine is combined with Mesalazine.
DB00246
The risk or severity of hypertension can be increased when Mesalazine is combined with Ziprasidone.
DB00247
The risk or severity of hypertension can be increased when Mesalazine is combined with Methysergide.
DB00248
The risk or severity of hypertension can be increased when Mesalazine is combined with Cabergoline.
DB00315
The risk or severity of hypertension can be increased when Mesalazine is combined with Zolmitriptan.
DB00320
The risk or severity of hypertension can be increased when Mesalazine is combined with Dihydroergotamine.
DB00344
The risk or severity of hypertension can be increased when Mesalazine is combined with Protriptyline.
DB00353
The risk or severity of hypertension can be increased when Mesalazine is combined with Methylergometrine.
DB00368
The risk or severity of hypertension can be increased when Mesalazine is combined with Norepinephrine.
DB00370
The risk or severity of hypertension can be increased when Mesalazine is combined with Mirtazapine.
DB00388
The risk or severity of hypertension can be increased when Mesalazine is combined with Phenylephrine.
DB00397
The risk or severity of hypertension can be increased when Mesalazine is combined with Phenylpropanolamine.
DB00420
The risk or severity of hypertension can be increased when Mesalazine is combined with Promazine.
DB00450
The risk or severity of hypertension can be increased when Mesalazine is combined with Droperidol.
DB00540
The risk or severity of hypertension can be increased when Mesalazine is combined with Nortriptyline.
DB00543
The risk or severity of hypertension can be increased when Mesalazine is combined with Amoxapine.
DB00561
The risk or severity of hypertension can be increased when Mesalazine is combined with Doxapram.
DB00572
The risk or severity of hypertension can be increased when Mesalazine is combined with Atropine.
DB00589
The risk or severity of hypertension can be increased when Mesalazine is combined with Lisuride.
DB00601
The risk or severity of hypertension can be increased when Mesalazine is combined with Linezolid.
DB00610
The risk or severity of hypertension can be increased when Mesalazine is combined with Metaraminol.
DB00614
The risk or severity of hypertension can be increased when Mesalazine is combined with Furazolidone.
DB00668
The risk or severity of hypertension can be increased when Mesalazine is combined with Epinephrine.
DB00679
The risk or severity of hypertension can be increased when Mesalazine is combined with Thioridazine.
DB00696
The risk or severity of hypertension can be increased when Mesalazine is combined with Ergotamine.
DB00699
The risk or severity of hypertension can be increased when Mesalazine is combined with Nicergoline.
DB00708
The risk or severity of hypertension can be increased when Mesalazine is combined with Sufentanil.
DB00723
The risk or severity of hypertension can be increased when Mesalazine is combined with Methoxamine.
DB00726
The risk or severity of hypertension can be increased when Mesalazine is combined with Trimipramine.
DB00734
The risk or severity of hypertension can be increased when Mesalazine is combined with Risperidone.
DB00752
The risk or severity of hypertension can be increased when Mesalazine is combined with Tranylcypromine.
DB00753
The risk or severity of hypertension can be increased when Mesalazine is combined with Isoflurane.
DB00777
The risk or severity of hypertension can be increased when Mesalazine is combined with Propiomazine.
DB00802
The risk or severity of hypertension can be increased when Mesalazine is combined with Alfentanil.
DB00805
The risk or severity of hypertension can be increased when Mesalazine is combined with Minaprine.
DB00816
The risk or severity of hypertension can be increased when Mesalazine is combined with Orciprenaline.
DB00818
The risk or severity of hypertension can be increased when Mesalazine is combined with Propofol.
DB00830
The risk or severity of hypertension can be increased when Mesalazine is combined with Phenmetrazine.
DB00831
The risk or severity of hypertension can be increased when Mesalazine is combined with Trifluoperazine.
DB00852
The risk or severity of hypertension can be increased when Mesalazine is combined with Pseudoephedrine.
DB00865
The risk or severity of hypertension can be increased when Mesalazine is combined with Benzphetamine.
DB00867
The risk or severity of hypertension can be increased when Mesalazine is combined with Ritodrine.
DB00875
The risk or severity of hypertension can be increased when Mesalazine is combined with Flupentixol.
DB00899
The risk or severity of hypertension can be increased when Mesalazine is combined with Remifentanil.
DB00901
The risk or severity of hypertension can be increased when Mesalazine is combined with Bitolterol.
DB00935
The risk or severity of hypertension can be increased when Mesalazine is combined with Oxymetazoline.
DB00937
The risk or severity of hypertension can be increased when Mesalazine is combined with Diethylpropion.
DB00938
The risk or severity of hypertension can be increased when Mesalazine is combined with Salmeterol.
DB00952
The risk or severity of hypertension can be increased when Mesalazine is combined with Naratriptan.
DB00983
The risk or severity of hypertension can be increased when Mesalazine is combined with Formoterol.
DB00998
The risk or severity of hypertension can be increased when Mesalazine is combined with Frovatriptan.
DB01028
The risk or severity of hypertension can be increased when Mesalazine is combined with Methoxyflurane.
DB01037
The risk or severity of hypertension can be increased when Mesalazine is combined with Selegiline.
DB01049
The risk or severity of hypertension can be increased when Mesalazine is combined with Ergoloid mesylate.
DB01064
The risk or severity of hypertension can be increased when Mesalazine is combined with Isoprenaline.
DB01102
The risk or severity of hypertension can be increased when Mesalazine is combined with Arbutamine.
DB01126
The risk or severity of hypertension can be increased when Mesalazine is combined with Dutasteride.
DB01159
The risk or severity of hypertension can be increased when Mesalazine is combined with Halothane.
DB01171
The risk or severity of hypertension can be increased when Mesalazine is combined with Moclobemide.
DB01186
The risk or severity of hypertension can be increased when Mesalazine is combined with Pergolide.
DB01189
The risk or severity of hypertension can be increased when Mesalazine is combined with Desflurane.
DB01216
The risk or severity of hypertension can be increased when Mesalazine is combined with Finasteride.
DB01238
The risk or severity of hypertension can be increased when Mesalazine is combined with Aripiprazole.
DB01247
The risk or severity of hypertension can be increased when Mesalazine is combined with Isocarboxazid.
DB01253
The risk or severity of hypertension can be increased when Mesalazine is combined with Ergometrine.
DB01255
The risk or severity of hypertension can be increased when Mesalazine is combined with Lisdexamfetamine.
DB01288
The risk or severity of hypertension can be increased when Mesalazine is combined with Fenoterol.
DB01291
The risk or severity of hypertension can be increased when Mesalazine is combined with Pirbuterol.
DB01363
The risk or severity of hypertension can be increased when Mesalazine is combined with Ephedra sinica root.
DB01364
The risk or severity of hypertension can be increased when Mesalazine is combined with Ephedrine.
DB01365
The risk or severity of hypertension can be increased when Mesalazine is combined with Mephentermine.
DB01366
The risk or severity of hypertension can be increased when Mesalazine is combined with Procaterol.
DB01392
The risk or severity of hypertension can be increased when Mesalazine is combined with Yohimbine.
DB01403
The risk or severity of hypertension can be increased when Mesalazine is combined with Methotrimeprazine.
DB01407
The risk or severity of hypertension can be increased when Mesalazine is combined with Clenbuterol.
DB01408
The risk or severity of hypertension can be increased when Mesalazine is combined with Bambuterol.
DB01442
The risk or severity of hypertension can be increased when Mesalazine is combined with MMDA.
DB01454
The risk or severity of hypertension can be increased when Mesalazine is combined with Midomafetamine.
DB01467
The risk or severity of hypertension can be increased when Mesalazine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
DB01472
The risk or severity of hypertension can be increased when Mesalazine is combined with 4-Methoxyamphetamine.
DB01484
The risk or severity of hypertension can be increased when Mesalazine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB01509
The risk or severity of hypertension can be increased when Mesalazine is combined with Tenamfetamine.
DB01556
The risk or severity of hypertension can be increased when Mesalazine is combined with Chlorphentermine.
DB01576
The risk or severity of hypertension can be increased when Mesalazine is combined with Dextroamphetamine.
DB01579
The risk or severity of hypertension can be increased when Mesalazine is combined with Phendimetrazine.
DB01591
The risk or severity of hypertension can be increased when Mesalazine is combined with Solifenacin.
DB01608
The risk or severity of hypertension can be increased when Mesalazine is combined with Periciazine.
DB01614
The risk or severity of hypertension can be increased when Mesalazine is combined with Acepromazine.
DB01622
The risk or severity of hypertension can be increased when Mesalazine is combined with Thioproperazine.
DB01624
The risk or severity of hypertension can be increased when Mesalazine is combined with Zuclopenthixol.
DB02032
The risk or severity of hypertension can be increased when Mesalazine is combined with Epicaptopril.
DB04017
The risk or severity of hypertension can be increased when Mesalazine is combined with Clorgiline.
DB04581
The risk or severity of hypertension can be increased when Mesalazine is combined with 1-benzylimidazole.
DB04818
The risk or severity of hypertension can be increased when Mesalazine is combined with Iproniazid.
DB04820
The risk or severity of hypertension can be increased when Mesalazine is combined with Nialamide.
DB04829
The risk or severity of hypertension can be increased when Mesalazine is combined with Lysergic acid diethylamide.
DB04836
The risk or severity of hypertension can be increased when Mesalazine is combined with Amineptine.
DB04855
The risk or severity of hypertension can be increased when Mesalazine is combined with Dronedarone.
DB04908
The risk or severity of hypertension can be increased when Mesalazine is combined with Flibanserin.
DB04946
The risk or severity of hypertension can be increased when Mesalazine is combined with Iloperidone.
DB05039
The risk or severity of hypertension can be increased when Mesalazine is combined with Indacaterol.
DB05271
The risk or severity of hypertension can be increased when Mesalazine is combined with Rotigotine.
DB05395
The risk or severity of hypertension can be increased when Mesalazine is combined with Amibegron.
DB05562
The risk or severity of hypertension can be increased when Mesalazine is combined with Naluzotan.
DB06016
The risk or severity of hypertension can be increased when Mesalazine is combined with Cariprazine.
DB06148
The risk or severity of hypertension can be increased when Mesalazine is combined with Mianserin.
DB06153
The risk or severity of hypertension can be increased when Mesalazine is combined with Pizotifen.
DB06190
The risk or severity of hypertension can be increased when Mesalazine is combined with Solabegron.
DB06654
The risk or severity of hypertension can be increased when Mesalazine is combined with Safinamide.
DB06678
The risk or severity of hypertension can be increased when Mesalazine is combined with Esmirtazapine.
DB06684
The risk or severity of hypertension can be increased when Mesalazine is combined with Vilazodone.
DB06690
The risk or severity of hypertension can be increased when Mesalazine is combined with Nitrous oxide.
DB06701
The risk or severity of hypertension can be increased when Mesalazine is combined with Dexmethylphenidate.
DB06706
The risk or severity of hypertension can be increased when Mesalazine is combined with Isometheptene.
DB06707
The risk or severity of hypertension can be increased when Mesalazine is combined with Levonordefrin.
DB06711
The risk or severity of hypertension can be increased when Mesalazine is combined with Naphazoline.
DB06764
The risk or severity of hypertension can be increased when Mesalazine is combined with Tetryzoline.
DB08810
The risk or severity of hypertension can be increased when Mesalazine is combined with Cinitapride.
DB08815
The risk or severity of hypertension can be increased when Mesalazine is combined with Lurasidone.
DB08841
The risk or severity of hypertension can be increased when Mesalazine is combined with Tyramine.
DB08925
The risk or severity of hypertension can be increased when Mesalazine is combined with Adrafinil.
DB08941
The risk or severity of hypertension can be increased when Mesalazine is combined with Isoxsuprine.
DB08954
The risk or severity of hypertension can be increased when Mesalazine is combined with Ifenprodil.
DB08957
The risk or severity of hypertension can be increased when Mesalazine is combined with Hexoprenaline.
DB08985
The risk or severity of hypertension can be increased when Mesalazine is combined with Etilefrine.
DB09016
The risk or severity of hypertension can be increased when Mesalazine is combined with Butriptyline.
DB09061
The risk or severity of hypertension can be increased when Mesalazine is combined with Cannabidiol.
DB09080
The risk or severity of hypertension can be increased when Mesalazine is combined with Olodaterol.
DB09128
The risk or severity of hypertension can be increased when Mesalazine is combined with Brexpiprazole.
DB09167
The risk or severity of hypertension can be increased when Mesalazine is combined with Dosulepin.
DB09202
The risk or severity of hypertension can be increased when Mesalazine is combined with Cirazoline.
DB09203
The risk or severity of hypertension can be increased when Mesalazine is combined with Synephrine.
DB09243
The risk or severity of hypertension can be increased when Mesalazine is combined with Hydracarbazine.
DB09246
The risk or severity of hypertension can be increased when Mesalazine is combined with Benmoxin.
DB09248
The risk or severity of hypertension can be increased when Mesalazine is combined with Mebanazine.
DB09249
The risk or severity of hypertension can be increased when Mesalazine is combined with Octamoxin.
DB09250
The risk or severity of hypertension can be increased when Mesalazine is combined with Pheniprazine.
DB09251
The risk or severity of hypertension can be increased when Mesalazine is combined with Phenoxypropazine.
DB09252
The risk or severity of hypertension can be increased when Mesalazine is combined with Pivhydrazine.
DB09253
The risk or severity of hypertension can be increased when Mesalazine is combined with Safrazine.
DB09254
The risk or severity of hypertension can be increased when Mesalazine is combined with Caroxazone.
DB09273
The risk or severity of hypertension can be increased when Mesalazine is combined with Doxofylline.
DB09289
The risk or severity of hypertension can be increased when Mesalazine is combined with Tianeptine.
DB09307
The risk or severity of hypertension can be increased when Mesalazine is combined with Oxaprotiline.
DB09480
The risk or severity of hypertension can be increased when Mesalazine is combined with Iofetamine I-123.
DB11124
The risk or severity of hypertension can be increased when Mesalazine is combined with Racepinephrine.
DB11273
The risk or severity of hypertension can be increased when Mesalazine is combined with Dihydroergocornine.
DB11373
The risk or severity of hypertension can be increased when Mesalazine is combined with Amitraz.
DB11428
The risk or severity of hypertension can be increased when Mesalazine is combined with Medetomidine.
DB11477
The risk or severity of hypertension can be increased when Mesalazine is combined with Xylazine.
DB11481
The risk or severity of hypertension can be increased when Mesalazine is combined with Atipamezole.
DB11541
The risk or severity of hypertension can be increased when Mesalazine is combined with Ractopamine.
DB11543
The risk or severity of hypertension can be increased when Mesalazine is combined with Romifidine.
DB11556
The risk or severity of hypertension can be increased when Mesalazine is combined with Detomidine.
DB11755
The risk or severity of hypertension can be increased when Mesalazine is combined with Tetrahydrocannabivarin.
DB11871
The risk or severity of hypertension can be increased when Mesalazine is combined with PF-00610355.
DB12080
The risk or severity of hypertension can be increased when Mesalazine is combined with Ritobegron.
DB12100
The risk or severity of hypertension can be increased when Mesalazine is combined with Abediterol.
DB12248
The risk or severity of hypertension can be increased when Mesalazine is combined with Tulobuterol.
DB12313
The risk or severity of hypertension can be increased when Mesalazine is combined with Dopexamine.
DB12361
The risk or severity of hypertension can be increased when Mesalazine is combined with Piclozotan.
DB12371
The risk or severity of hypertension can be increased when Mesalazine is combined with Siponimod.
DB12551
The risk or severity of hypertension can be increased when Mesalazine is combined with Idazoxan.
DB12779
The risk or severity of hypertension can be increased when Mesalazine is combined with Higenamine.
DB12846
The risk or severity of hypertension can be increased when Mesalazine is combined with Reproterol.
DB12927
The risk or severity of hypertension can be increased when Mesalazine is combined with Theodrenaline.
DB12930
The risk or severity of hypertension can be increased when Mesalazine is combined with Opipramol.
DB13064
The risk or severity of hypertension can be increased when Mesalazine is combined with Tramazoline.
DB13108
The risk or severity of hypertension can be increased when Mesalazine is combined with Mephedrone.
DB13114
The risk or severity of hypertension can be increased when Mesalazine is combined with Amitriptylinoxide.
DB13225
The risk or severity of hypertension can be increased when Mesalazine is combined with Dibenzepin.
DB13246
The risk or severity of hypertension can be increased when Mesalazine is combined with Quinupramine.
DB13251
The risk or severity of hypertension can be increased when Mesalazine is combined with Octopamine.
DB13323
The risk or severity of hypertension can be increased when Mesalazine is combined with Trichloroethylene.
DB13341
The risk or severity of hypertension can be increased when Mesalazine is combined with Fenozolone.
DB13345
The risk or severity of hypertension can be increased when Mesalazine is combined with Dihydroergocristine.
DB13378
The risk or severity of hypertension can be increased when Mesalazine is combined with Norfenefrine.
DB13384
The risk or severity of hypertension can be increased when Mesalazine is combined with Melitracen.
DB13385
The risk or severity of hypertension can be increased when Mesalazine is combined with Dihydroergocryptine.
DB13398
The risk or severity of hypertension can be increased when Mesalazine is combined with Oxyfedrine.
DB13399
The risk or severity of hypertension can be increased when Mesalazine is combined with Terguride.
DB13411
The risk or severity of hypertension can be increased when Mesalazine is combined with Lofepramine.
DB13453
The risk or severity of hypertension can be increased when Mesalazine is combined with Xenon.
DB13496
The risk or severity of hypertension can be increased when Mesalazine is combined with Iprindole.
DB13520
The risk or severity of hypertension can be increased when Mesalazine is combined with Metergoline.
DB13559
The risk or severity of hypertension can be increased when Mesalazine is combined with Rimiterol.
DB13598
The risk or severity of hypertension can be increased when Mesalazine is combined with Diethyl ether.
DB13624
The risk or severity of hypertension can be increased when Mesalazine is combined with Methoxyphenamine.
DB13692
The risk or severity of hypertension can be increased when Mesalazine is combined with Tretoquinol.
DB13703
The risk or severity of hypertension can be increased when Mesalazine is combined with Gepefrine.
DB13777
The risk or severity of hypertension can be increased when Mesalazine is combined with Prenalterol.
DB13781
The risk or severity of hypertension can be increased when Mesalazine is combined with Xamoterol.
DB13782
The risk or severity of hypertension can be increased when Mesalazine is combined with Imipramine oxide.
DB13852
The risk or severity of hypertension can be increased when Mesalazine is combined with Mefenorex.
DB13875
The risk or severity of hypertension can be increased when Mesalazine is combined with Harmaline.
DB13917
The risk or severity of hypertension can be increased when Mesalazine is combined with Deoxyepinephrine.
DB13940
The risk or severity of hypertension can be increased when Mesalazine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB14010
The risk or severity of hypertension can be increased when Mesalazine is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14185
The risk or severity of hypertension can be increased when Mesalazine is combined with Aripiprazole lauroxil.
DB06694
The risk or severity of hypertension can be increased when Mesalazine is combined with Xylometazoline.
DB15685
The risk or severity of hypertension can be increased when Mesalazine is combined with Selpercatinib.
DB15965
The risk or severity of hypertension can be increased when Mesalazine is combined with Naxitamab.
DB06767
The serum concentration of Mesalazine can be increased when it is combined with Ammonium chloride.
DB01381
Ginkgo biloba may increase the anticoagulant activities of Mesalazine.
DB06813
The serum concentration of Pralatrexate can be increased when it is combined with Mesalazine.
DB09026
The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Aliskiren.
DB01609
The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Mesalazine is combined with Deferasirox.
DB00035
The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Mesalazine is combined with Desmopressin.
DB00390
Mesalazine may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB13401
Mesalazine may decrease the excretion rate of Metildigoxin which could result in a higher serum level.
DB13691
Mesalazine may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.
DB01395
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Drospirenone.
DB00502
The therapeutic efficacy of Haloperidol can be increased when used in combination with Mesalazine.
DB01275
Mesalazine may decrease the antihypertensive activities of Hydralazine.
DB14507
Mesalazine may decrease the excretion rate of Lithium citrate which could result in a higher serum level.
DB14509
Mesalazine may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
DB14506
Mesalazine may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB00563
The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.
DB00642
Mesalazine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB01032
Probenecid may decrease the excretion rate of Mesalazine which could result in a higher serum level.
DB00374
The risk or severity of bleeding can be increased when Treprostinil is combined with Mesalazine.
DB00512
Mesalazine may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00529
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Foscarnet.
DB00742
The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Mesalazine.
DB00300
Mesalazine may increase the nephrotoxic activities of Tenofovir disoproxil.
DB09299
Mesalazine may increase the nephrotoxic activities of Tenofovir alafenamide.
DB14126
Mesalazine may increase the nephrotoxic activities of Tenofovir.
DB00630
The risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.
DB00501
Cimetidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00585
Nizatidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00863
Ranitidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00927
Famotidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00940
Methantheline can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01377
Magnesium oxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01390
Sodium bicarbonate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06723
Aluminum hydroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06724
Calcium carbonate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08805
Metiamide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08806
Roxatidine acetate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08938
Magaldrate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09104
Magnesium hydroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09281
Magnesium trisilicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09481
Magnesium carbonate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12770
Lafutidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12884
Lavoltidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13209
Bismuth subnitrate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13249
Magnesium silicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13280
Aluminium acetoacetate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13322
Hydrotalcite can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13486
Magnesium peroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13595
Almasilate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13626
Aluminium glycinate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13650
Aloglutamol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13760
Niperotidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13829
Calcium silicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14517
Aluminium phosphate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00213
Mesalazine can cause a decrease in the absorption of Pantoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01129
Mesalazine can cause a decrease in the absorption of Rabeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00338
Omeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00448
Lansoprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00736
Esomeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB05351
Dexlansoprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13762
Dexrabeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB15246
Salvianolic acid A can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14048
Sodium zirconium cyclosilicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00334
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine.
DB01069
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Promethazine.
DB01142
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.
DB06216
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Asenapine.
DB00751
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Epinastine.
DB00001
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Lepirudin.
DB00006
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Bivalirudin.
DB00009
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Alteplase.
DB00013
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Urokinase.
DB00015
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Reteplase.
DB00029
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Anistreplase.
DB00031
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tenecteplase.
DB00054
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Abciximab.
DB00055
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Drotrecogin alfa.
DB00086
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Streptokinase.
DB00266
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dicoumarol.
DB00278
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Argatroban.
DB00407
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ardeparin.
DB00498
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Phenindione.
DB00569
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Fondaparinux.
DB00682
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Warfarin.
DB00686
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Pentosan polysulfate.
DB00946
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Phenprocoumon.
DB00975
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dipyridamole.
DB01088
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Iloprost.
DB01109
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Heparin.
DB01225
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Enoxaparin.
DB01240
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Epoprostenol.
DB01418
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Acenocoumarol.
DB03410
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with 4-hydroxycoumarin.
DB04665
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Coumarin.
DB04898
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ximelagatran.
DB04925
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Desmoteplase.
DB04932
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Defibrotide.
DB05099
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ancrod.
DB05229
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Beraprost.
DB05254
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Fibrinolysin.
DB06209
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Prasugrel.
DB06228
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Rivaroxaban.
DB06271
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Sulodexide.
DB06294
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Semuloparin.
DB06406
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Idraparinux.
DB06441
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Cangrelor.
DB06543
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Astaxanthin.
DB06605
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Apixaban.
DB06635
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Otamixaban.
DB06679
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Amediplase.
DB06695
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dabigatran etexilate.
DB06754
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Danaparoid.
DB06779
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dalteparin.
DB06822
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tinzaparin.
DB07767
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ferulic acid.
DB08496
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with (R)-warfarin.
DB08794
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ethyl biscoumacetate.
DB08813
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Nadroparin.
DB08814
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Triflusal.
DB08816
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ticagrelor.
DB08994
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ditazole.
DB09030
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Vorapaxar.
DB09075
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Edoxaban.
DB09125
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Potassium citrate.
DB09154
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Sodium citrate.
DB09255
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dextran.
DB09258
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Bemiparin.
DB09260
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Parnaparin.
DB11095
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Desirudin.
DB11154
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Zinc citrate.
DB11166
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Antithrombin Alfa.
DB11312
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Protein C.
DB11598
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Antithrombin III human.
DB11984
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Letaxaban.
DB12289
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Darexaban.
DB12598
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Nafamostat.
DB12726
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Monteplase.
DB12831
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Gabexate.
DB13136
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Fluindione.
DB13149
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Protein S human.
DB13199
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Brinase.
DB13275
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Clorindione.
DB13347
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Diphenadione.
DB13451
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tioclomarol.
DB13616
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Melagatran.
DB13646
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Saruplase.
DB14055
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with (S)-Warfarin.
DB14094
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tocopherylquinone.
DB14598
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Edetate calcium disodium anhydrous.
DB14726
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dabigatran.
DB09259
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Reviparin.
DB13124
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Troxerutin.
DB00974
The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Edetic acid.
DB00177
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Mesalazine.
DB00275
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Mesalazine.
DB00678
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Mesalazine.
DB00796
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Mesalazine.
DB00876
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Mesalazine.
DB00966
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Mesalazine.
DB01029
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Mesalazine.
DB01342
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Mesalazine.
DB01347
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Mesalazine.
DB01349
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Mesalazine.
DB06763
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Mesalazine.
DB08822
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Mesalazine.
DB09279
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Mesalazine.
DB13919
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Mesalazine.
DB00178
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Ramipril.
DB00492
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Fosinopril.
DB00519
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Trandolapril.
DB00542
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Benazepril.
DB00584
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Enalapril.
DB00691
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Moexipril.
DB00722
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Lisinopril.
DB00790
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Perindopril.
DB00881
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Quinapril.
DB00886
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Omapatrilat.
DB01180
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Rescinnamine.
DB01197
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Captopril.
DB01340
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Cilazapril.
DB01348
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Spirapril.
DB08836
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Temocapril.
DB09477
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Enalaprilat.
DB11783
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Imidapril.
DB13166
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Zofenopril.
DB13312
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Delapril.
DB14125
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Benazeprilat.
DB14207
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Fosinoprilat.
DB14208
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Ramiprilat.
DB14209
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Trandolaprilat.
DB14210
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Moexiprilat.
DB14213
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Perindoprilat.
DB14217
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Quinaprilat.
DB14231
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Quinoline Yellow WS.
DB15565
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Cilazaprilat.
DB00187
Mesalazine may decrease the antihypertensive activities of Esmolol.
DB00195
Mesalazine may decrease the antihypertensive activities of Betaxolol.
DB00264
Mesalazine may decrease the antihypertensive activities of Metoprolol.
DB00335
Mesalazine may decrease the antihypertensive activities of Atenolol.
DB00373
Mesalazine may decrease the antihypertensive activities of Timolol.
DB00489
Mesalazine may decrease the antihypertensive activities of Sotalol.
DB00571
Mesalazine may decrease the antihypertensive activities of Propranolol.
DB00598
Mesalazine may decrease the antihypertensive activities of Labetalol.
DB00612
Mesalazine may decrease the antihypertensive activities of Bisoprolol.
DB00866
Mesalazine may decrease the antihypertensive activities of Alprenolol.
DB00960
Mesalazine may decrease the antihypertensive activities of Pindolol.
DB01136
Mesalazine may decrease the antihypertensive activities of Carvedilol.
DB01182
Mesalazine may decrease the antihypertensive activities of Propafenone.
DB01193
Mesalazine may decrease the antihypertensive activities of Acebutolol.
DB01203
Mesalazine may decrease the antihypertensive activities of Nadolol.
DB01295
Mesalazine may decrease the antihypertensive activities of Bevantolol.
DB01297
Mesalazine may decrease the antihypertensive activities of Practolol.
DB01359
Mesalazine may decrease the antihypertensive activities of Penbutolol.
DB01580
Mesalazine may decrease the antihypertensive activities of Oxprenolol.
DB03322
Mesalazine may decrease the antihypertensive activities of Dexpropranolol.
DB04846
Mesalazine may decrease the antihypertensive activities of Celiprolol.
DB04861
Mesalazine may decrease the antihypertensive activities of Nebivolol.
DB06726
Mesalazine may decrease the antihypertensive activities of Bufuralol.
DB08807
Mesalazine may decrease the antihypertensive activities of Bopindolol.
DB08808
Mesalazine may decrease the antihypertensive activities of Bupranolol.
DB08952
Mesalazine may decrease the antihypertensive activities of Indenolol.
DB09204
Mesalazine may decrease the antihypertensive activities of Arotinolol.
DB09351
Mesalazine may decrease the antihypertensive activities of Levobetaxolol.
DB11770
Mesalazine may decrease the antihypertensive activities of Talinolol.
DB11785
Mesalazine may decrease the antihypertensive activities of Anisodamine.
DB12752
Mesalazine may decrease the antihypertensive activities of Bucindolol.
DB13443
Mesalazine may decrease the antihypertensive activities of Esatenolol.
DB13508
Mesalazine may decrease the antihypertensive activities of Cloranolol.
DB13530
Mesalazine may decrease the antihypertensive activities of Mepindolol.
DB13757
Mesalazine may decrease the antihypertensive activities of Epanolol.
DB13775
Mesalazine may decrease the antihypertensive activities of Tertatolol.
DB12212
Mesalazine may decrease the antihypertensive activities of Landiolol.
DB00214
The therapeutic efficacy of Torasemide can be decreased when used in combination with Mesalazine.
DB00887
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Mesalazine.
DB00903
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mesalazine.
DB02925
The therapeutic efficacy of Piretanide can be decreased when used in combination with Mesalazine.
DB08961
The therapeutic efficacy of Azosemide can be decreased when used in combination with Mesalazine.
DB00218
Mesalazine may increase the neuroexcitatory activities of Moxifloxacin.
DB00365
Mesalazine may increase the neuroexcitatory activities of Grepafloxacin.
DB00467
Mesalazine may increase the neuroexcitatory activities of Enoxacin.
DB00487
Mesalazine may increase the neuroexcitatory activities of Pefloxacin.
DB00685
Mesalazine may increase the neuroexcitatory activities of Trovafloxacin.
DB00779
Mesalazine may increase the neuroexcitatory activities of Nalidixic acid.
DB00817
Mesalazine may increase the neuroexcitatory activities of Rosoxacin.
DB00827
Mesalazine may increase the neuroexcitatory activities of Cinoxacin.
DB00978
Mesalazine may increase the neuroexcitatory activities of Lomefloxacin.
DB01044
Mesalazine may increase the neuroexcitatory activities of Gatifloxacin.
DB01059
Mesalazine may increase the neuroexcitatory activities of Norfloxacin.
DB01155
Mesalazine may increase the neuroexcitatory activities of Gemifloxacin.
DB01165
Mesalazine may increase the neuroexcitatory activities of Ofloxacin.
DB01208
Mesalazine may increase the neuroexcitatory activities of Sparfloxacin.
DB01405
Mesalazine may increase the neuroexcitatory activities of Temafloxacin.
DB04576
Mesalazine may increase the neuroexcitatory activities of Fleroxacin.
DB05488
Mesalazine may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.
DB06160
Mesalazine may increase the neuroexcitatory activities of Garenoxacin.
DB06600
Mesalazine may increase the neuroexcitatory activities of Nemonoxacin.
DB08972
Mesalazine may increase the neuroexcitatory activities of Flumequine.
DB11404
Mesalazine may increase the neuroexcitatory activities of Enrofloxacin.
DB11443
Mesalazine may increase the neuroexcitatory activities of Orbifloxacin.
DB11491
Mesalazine may increase the neuroexcitatory activities of Sarafloxacin.
DB11511
Mesalazine may increase the neuroexcitatory activities of Difloxacin.
DB11774
Mesalazine may increase the neuroexcitatory activities of Pazufloxacin.
DB11892
Mesalazine may increase the neuroexcitatory activities of Prulifloxacin.
DB13261
Mesalazine may increase the neuroexcitatory activities of Sitafloxacin.
DB13627
Mesalazine may increase the neuroexcitatory activities of Oxolinic acid.
DB13772
Mesalazine may increase the neuroexcitatory activities of Rufloxacin.
DB13823
Mesalazine may increase the neuroexcitatory activities of Pipemidic acid.
DB00232
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.
DB00310
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mesalazine.
DB00436
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mesalazine.
DB00524
The therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.
DB00562
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mesalazine.
DB00774
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mesalazine.
DB00808
The therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.
DB00880
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.
DB00999
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mesalazine.
DB01021
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mesalazine.
DB01324
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Mesalazine.
DB01325
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Mesalazine.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mesalazine.
DB13989
The therapeutic efficacy of Epitizide can be decreased when used in combination with Mesalazine.
DB01009
The risk or severity of bleeding and gastrointestinal bleeding can be increased when Mesalazine is combined with Ketoprofen.
DB09214
The risk or severity of bleeding and gastrointestinal bleeding can be increased when Mesalazine is combined with Dexketoprofen.
DB00511
The serum concentration of Acetyldigitoxin can be decreased when it is combined with Mesalazine.
DB01078
The serum concentration of Deslanoside can be decreased when it is combined with Mesalazine.
DB01092
The serum concentration of Ouabain can be decreased when it is combined with Mesalazine.
DB01396
The serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.
DB12843
The serum concentration of Oleandrin can be decreased when it is combined with Mesalazine.
DB13240
The serum concentration of Cymarin can be decreased when it is combined with Mesalazine.
DB13307
The serum concentration of Proscillaridin can be decreased when it is combined with Mesalazine.
DB13467
The serum concentration of Lanatoside C can be decreased when it is combined with Mesalazine.
DB13537
The serum concentration of Gitoformate can be decreased when it is combined with Mesalazine.
DB13756
The serum concentration of Peruvoside can be decreased when it is combined with Mesalazine.
DB00282
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Pamidronic acid.
DB00399
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Zoledronic acid.
DB00710
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Ibandronate.
DB00720
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Clodronic acid.
DB00884
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Risedronic acid.
DB01077
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Etidronic acid.
DB01133
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Tiludronic acid.
DB06255
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Incadronic acid.
DB00287
The therapeutic efficacy of Travoprost can be decreased when used in combination with Mesalazine.
DB00654
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Mesalazine.
DB00905
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mesalazine.
DB01160
The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Mesalazine.
DB02056
The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mesalazine.
DB02304
The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mesalazine.
DB03866
The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mesalazine.
DB06826
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Mesalazine.
DB08819
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Mesalazine.
DB09211
The therapeutic efficacy of Limaprost can be decreased when used in combination with Mesalazine.
DB11411
The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mesalazine.
DB11425
The therapeutic efficacy of Luprostiol can be decreased when used in combination with Mesalazine.
DB11454
The therapeutic efficacy of Prostalene can be decreased when used in combination with Mesalazine.
DB11507
The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mesalazine.
DB11519
The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mesalazine.
DB11660
The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mesalazine.
DB13824
The therapeutic efficacy of Enprostil can be decreased when used in combination with Mesalazine.
DB04865
The risk or severity of bleeding can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.
DB00864
The risk or severity of renal failure can be increased when Mesalazine is combined with Tacrolimus.
DB00352
The metabolism of Tioguanine can be decreased when combined with Mesalazine.
DB01033
The metabolism of Mercaptopurine can be decreased when combined with Mesalazine.
DB00375
Colestipol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00658
Sevelamer can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00930
Colesevelam can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01432
Cholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00384
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Triamterene.
DB00421
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Spironolactone.
DB00594
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Amiloride.
DB00700
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Eplerenone.
DB09015
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Canrenoic acid.
DB12221
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Canrenone.
DB00229
The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Mesalazine.
DB00267
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefmenoxime.
DB00274
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefmetazole.
DB00430
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefpiramide.
DB00447
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Loracarbef.
DB00456
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefalotin.
DB00493
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefotaxime.
DB00626
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bacitracin.
DB00681
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Amphotericin B.
DB00689
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cephaloglycin.
DB00718
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Adefovir dipivoxil.
DB00923
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceforanide.
DB01066
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefditoren.
DB01072
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Atazanavir.
DB01111
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Colistimethate.
DB01112
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefuroxime.
DB01139
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefapirin.
DB01150
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefprozil.
DB01326
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefamandole.
DB01327
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefazolin.
DB01328
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefonicid.
DB01329
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefoperazone.
DB01331
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefoxitin.
DB01332
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftizoxime.
DB01413
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefepime.
DB01414
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefacetrile.
DB01416
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefpodoxime.
DB01601
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Lopinavir.
DB02247
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Hydrolyzed Cephalothin.
DB03450
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cephalothin Group.
DB04570
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Latamoxef.
DB04918
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftobiprole.
DB06590
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftaroline fosamil.
DB09008
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefaloridine.
DB09062
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefminox.
DB11935
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Flomoxef.
DB13266
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefatrizine.
DB13461
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefcapene.
DB13470
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefodizime.
DB13499
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefsulodin.
DB13504
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefetamet.
DB13638
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefbuperazone.
DB13667
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefozopran.
DB13682
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefpirome.
DB13778
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefazedone.
DB13821
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftezole.
DB13868
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Adefovir.
DB14713
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Inotersen.
DB01438
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Phenazopyridine.
DB15066
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Givosiran.
DB00452
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Framycetin.
DB01421
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Paromomycin.
DB04263
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Geneticin.
DB04626
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Apramycin.
DB04808
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neamine.
DB08437
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Puromycin.
DB11512
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Dihydrostreptomycin.
DB11520
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Hygromycin B.
DB01356
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Lithium cation.
DB00215
The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Mesalazine.
DB00472
The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Mesalazine.
DB00656
The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Mesalazine.
DB01175
The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Mesalazine.
DB04832
The risk or severity of gastrointestinal bleeding can be increased when Zimelidine is combined with Mesalazine.
DB04884
The risk or severity of gastrointestinal bleeding can be increased when Dapoxetine is combined with Mesalazine.
DB06731
The risk or severity of gastrointestinal bleeding can be increased when Seproxetine is combined with Mesalazine.
DB08953
The risk or severity of gastrointestinal bleeding can be increased when Indalpine is combined with Mesalazine.
DB12693
The risk or severity of gastrointestinal bleeding can be increased when Ritanserin is combined with Mesalazine.
DB13233
The risk or severity of gastrointestinal bleeding can be increased when Alaproclate is combined with Mesalazine.
DB00476
The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Mesalazine.
DB01105
The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Mesalazine.
DB04896
The risk or severity of gastrointestinal bleeding can be increased when Milnacipran is combined with Mesalazine.
DB06700
The risk or severity of gastrointestinal bleeding can be increased when Desvenlafaxine is combined with Mesalazine.
DB08918
The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Mesalazine.
DB00176
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Fluvoxamine.
DB01149
The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Nefazodone.
DB00715
The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Mesalazine.
DB00834
Mesalazine may increase the hypoglycemic activities of Mifepristone.
DB00030
Mesalazine may increase the hypoglycemic activities of Insulin human.
DB00046
Mesalazine may increase the hypoglycemic activities of Insulin lispro.
DB00047
Mesalazine may increase the hypoglycemic activities of Insulin glargine.
DB00071
Mesalazine may increase the hypoglycemic activities of Insulin pork.
DB00197
Mesalazine may increase the hypoglycemic activities of Troglitazone.
DB00222
Mesalazine may increase the hypoglycemic activities of Glimepiride.
DB00263
Mesalazine may increase the hypoglycemic activities of Sulfisoxazole.
DB00280
Mesalazine may increase the hypoglycemic activities of Disopyramide.
DB00284
Mesalazine may increase the hypoglycemic activities of Acarbose.
DB00331
Mesalazine may increase the hypoglycemic activities of Metformin.
DB00359
Mesalazine may increase the hypoglycemic activities of Sulfadiazine.
DB00412
Mesalazine may increase the hypoglycemic activities of Rosiglitazone.
DB00414
Mesalazine may increase the hypoglycemic activities of Acetohexamide.
DB00468
Mesalazine may increase the hypoglycemic activities of Quinine.
DB00491
Mesalazine may increase the hypoglycemic activities of Miglitol.
DB00672
Mesalazine may increase the hypoglycemic activities of Chlorpropamide.
DB00731
Mesalazine may increase the hypoglycemic activities of Nateglinide.
DB00738
Mesalazine may increase the hypoglycemic activities of Pentamidine.
DB00839
Mesalazine may increase the hypoglycemic activities of Tolazamide.
DB00912
Mesalazine may increase the hypoglycemic activities of Repaglinide.
DB00914
Mesalazine may increase the hypoglycemic activities of Phenformin.
DB01015
Mesalazine may increase the hypoglycemic activities of Sulfamethoxazole.
DB01016
Mesalazine may increase the hypoglycemic activities of Glyburide.
DB01067
Mesalazine may increase the hypoglycemic activities of Glipizide.
DB01120
Mesalazine may increase the hypoglycemic activities of Gliclazide.
DB01124
Mesalazine may increase the hypoglycemic activities of Tolbutamide.
DB01132
Mesalazine may increase the hypoglycemic activities of Pioglitazone.
DB01200
Mesalazine may increase the hypoglycemic activities of Bromocriptine.
DB01251
Mesalazine may increase the hypoglycemic activities of Gliquidone.
DB01252
Mesalazine may increase the hypoglycemic activities of Mitiglinide.
DB01261
Mesalazine may increase the hypoglycemic activities of Sitagliptin.
DB01268
Mesalazine may increase the hypoglycemic activities of Sunitinib.
DB01276
Mesalazine may increase the hypoglycemic activities of Exenatide.
DB01277
Mesalazine may increase the hypoglycemic activities of Mecasermin.
DB01278
Mesalazine may increase the hypoglycemic activities of Pramlintide.
DB01289
Mesalazine may increase the hypoglycemic activities of Glisoxepide.
DB01306
Mesalazine may increase the hypoglycemic activities of Insulin aspart.
DB01307
Mesalazine may increase the hypoglycemic activities of Insulin detemir.
DB01309
Mesalazine may increase the hypoglycemic activities of Insulin glulisine.
DB01382
Mesalazine may increase the hypoglycemic activities of Glymidine.
DB01700
Mesalazine may increase the hypoglycemic activities of AICA ribonucleotide.
DB04830
Mesalazine may increase the hypoglycemic activities of Buformin.
DB04876
Mesalazine may increase the hypoglycemic activities of Vildagliptin.
DB04878
Mesalazine may increase the hypoglycemic activities of Voglibose.
DB05115
Mesalazine may increase the hypoglycemic activities of NN344.
DB05819
Mesalazine may increase the hypoglycemic activities of NBI-6024.
DB06011
Mesalazine may increase the hypoglycemic activities of AMG-222.
DB06127
Mesalazine may increase the hypoglycemic activities of Bisegliptin.
DB06203
Mesalazine may increase the hypoglycemic activities of Alogliptin.
DB06292
Mesalazine may increase the hypoglycemic activities of Dapagliflozin.
DB06335
Mesalazine may increase the hypoglycemic activities of Saxagliptin.
DB06655
Mesalazine may increase the hypoglycemic activities of Liraglutide.
DB08382
Mesalazine may increase the hypoglycemic activities of Gosogliptin.
DB08882
Mesalazine may increase the hypoglycemic activities of Linagliptin.
DB08907
Mesalazine may increase the hypoglycemic activities of Canagliflozin.
DB08962
Mesalazine may increase the hypoglycemic activities of Glibornuride.
DB09022
Mesalazine may increase the hypoglycemic activities of Benfluorex.
DB09038
Mesalazine may increase the hypoglycemic activities of Empagliflozin.
DB09043
Mesalazine may increase the hypoglycemic activities of Albiglutide.
DB09045
Mesalazine may increase the hypoglycemic activities of Dulaglutide.
DB09198
Mesalazine may increase the hypoglycemic activities of Lobeglitazone.
DB09199
Mesalazine may increase the hypoglycemic activities of Netoglitazone.
DB09200
Mesalazine may increase the hypoglycemic activities of Rivoglitazone.
DB09201
Mesalazine may increase the hypoglycemic activities of Ciglitazone.
DB09265
Mesalazine may increase the hypoglycemic activities of Lixisenatide.
DB09456
Mesalazine may increase the hypoglycemic activities of Insulin beef.
DB09564
Mesalazine may increase the hypoglycemic activities of Insulin degludec.
DB11567
Mesalazine may increase the hypoglycemic activities of Insulin peglispro.
DB11568
Mesalazine may increase the hypoglycemic activities of Insulin tregopil.
DB11698
Mesalazine may increase the hypoglycemic activities of Ipragliflozin.
DB11723
Mesalazine may increase the hypoglycemic activities of Dutogliptin.
DB11780
Mesalazine may increase the hypoglycemic activities of Allicin.
DB11824
Mesalazine may increase the hypoglycemic activities of Tofogliflozin.
DB11827
Mesalazine may increase the hypoglycemic activities of Ertugliflozin.
DB11898
Mesalazine may increase the hypoglycemic activities of 2,4-thiazolidinedione.
DB11950
Mesalazine may increase the hypoglycemic activities of Teneligliptin.
DB11992
Mesalazine may increase the hypoglycemic activities of Omarigliptin.
DB12268
Mesalazine may increase the hypoglycemic activities of Carmegliptin.
DB12412
Mesalazine may increase the hypoglycemic activities of Gemigliptin.
DB12417
Mesalazine may increase the hypoglycemic activities of Anagliptin.
DB12625
Mesalazine may increase the hypoglycemic activities of Evogliptin.
DB12713
Mesalazine may increase the hypoglycemic activities of Sotagliflozin.
DB12781
Mesalazine may increase the hypoglycemic activities of Balaglitazone.
DB12935
Mesalazine may increase the hypoglycemic activities of Remogliflozin etabonate.
DB13406
Mesalazine may increase the hypoglycemic activities of Carbutamide.
DB13446
Mesalazine may increase the hypoglycemic activities of Guar gum.
DB13675
Mesalazine may increase the hypoglycemic activities of Metahexamide.
DB13928
Mesalazine may increase the hypoglycemic activities of Semaglutide.
DB14027
Mesalazine may increase the hypoglycemic activities of Taspoglutide.
DB14035
Mesalazine may increase the hypoglycemic activities of Englitazone.
DB15171
Mesalazine may increase the hypoglycemic activities of Tirzepatide.
DB15217
Mesalazine may increase the hypoglycemic activities of Gastric inhibitory polypeptide.
DB00311
The risk or severity of adverse effects can be increased when Mesalazine is combined with Ethoxzolamide.
DB00703
The risk or severity of adverse effects can be increased when Mesalazine is combined with Methazolamide.
DB00819
The risk or severity of adverse effects can be increased when Mesalazine is combined with Acetazolamide.
DB00909
The risk or severity of adverse effects can be increased when Mesalazine is combined with Zonisamide.
DB01144
The risk or severity of adverse effects can be increased when Mesalazine is combined with Diclofenamide.
DB00313
The serum concentration of Valproic acid can be increased when it is combined with Mesalazine.
DB00159
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Icosapent.
DB00233
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Mesalazine.
DB00795
The therapeutic efficacy of Sulfasalazine can be decreased when used in combination with Mesalazine.
DB00861
The therapeutic efficacy of Diflunisal can be decreased when used in combination with Mesalazine.
DB00945
The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Mesalazine.
DB01014
The therapeutic efficacy of Balsalazide can be decreased when used in combination with Mesalazine.
DB01250
The therapeutic efficacy of Olsalazine can be decreased when used in combination with Mesalazine.
DB01294
The therapeutic efficacy of Bismuth subsalicylate can be decreased when used in combination with Mesalazine.
DB06251
The therapeutic efficacy of Dersalazine can be decreased when used in combination with Mesalazine.
DB06807
The therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Mesalazine.
DB09543
The therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Mesalazine.
DB11079
The therapeutic efficacy of Trolamine salicylate can be decreased when used in combination with Mesalazine.
DB12445
The therapeutic efficacy of Nitroaspirin can be decreased when used in combination with Mesalazine.
DB13509
The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Mesalazine.
DB13538
The therapeutic efficacy of Guacetisal can be decreased when used in combination with Mesalazine.
DB13612
The therapeutic efficacy of Carbaspirin calcium can be decreased when used in combination with Mesalazine.
DB14006
The therapeutic efficacy of Choline salicylate can be decreased when used in combination with Mesalazine.
DB14026
The therapeutic efficacy of Thiosalicylic acid can be decreased when used in combination with Mesalazine.
DB00328
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Indomethacin.
DB00461
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Nabumetone.
DB00469
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Tenoxicam.
DB00500
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Tolmetin.
DB00554
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Piroxicam.
DB00573
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Fenoprofen.
DB00586
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Diclofenac.
DB00605
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Sulindac.
DB00712
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Flurbiprofen.
DB00749
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Etodolac.
DB00784
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Mefenamic acid.
DB00788
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Naproxen.
DB00812
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Phenylbutazone.
DB00814
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Meloxicam.
DB00821
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Carprofen.
DB00870
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Suprofen.
DB00939
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Meclofenamic acid.
DB00963
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Bromfenac.
DB00991
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Oxaprozin.
DB01397
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium salicylate.
DB01399
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Salsalate.
DB01401
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Choline magnesium trisalicylate.
DB01419
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Antrafenine.
DB01435
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Antipyrine.
DB01600
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Tiaprofenic acid.
DB06725
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Lornoxicam.
DB06736
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Aceclofenac.
DB06802
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Nepafenac.
DB09213
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Dexibuprofen.
DB09215
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Droxicam.
DB13346
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Bufexamac.
DB00343
The risk or severity of bleeding can be increased when Diltiazem is combined with Mesalazine.
DB00661
The risk or severity of bleeding can be increased when Verapamil is combined with Mesalazine.
DB00285
Venlafaxine may increase the antiplatelet activities of Mesalazine.
DB00180
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Flunisolide.
DB00443
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Betamethasone.
DB00620
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Triamcinolone.
DB00635
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Prednisone.
DB00687
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Fludrocortisone.
DB00741
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Hydrocortisone.
DB00860
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Prednisolone.
DB00959
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Methylprednisolone.
DB01108
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Trilostane.
DB01222
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Budesonide.
DB01234
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Dexamethasone.
DB01285
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Corticotropin.
DB01380
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Cortisone acetate.
DB01384
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Paramethasone.
DB04630
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Aldosterone.
DB09378
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Fluprednisolone.
DB09383
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Meprednisone.
DB11529
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Melengestrol.
DB11921
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Deflazacort.
DB13003
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Cortivazol.
DB13208
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Prednylidene.
DB13843
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Cloprednol.
DB14681
The risk or severity of gastrointestinal irritation can be increased when Mesalazine is combined with Cortisone.
DB00394
The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Mesalazine.
DB00588
The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Mesalazine.
DB00591
The risk or severity of gastrointestinal irritation can be increased when Fluocinolone acetonide is combined with Mesalazine.
DB01410
The risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Mesalazine.
DB08906
The risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Mesalazine.
DB08970
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Mesalazine.
DB09091
The risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Mesalazine.
DB11487
The risk or severity of gastrointestinal irritation can be increased when Dexamethasone isonicotinate is combined with Mesalazine.
DB13223
The risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Mesalazine.
DB13491
The risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Mesalazine.
DB13856
The risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Mesalazine.
DB13867
The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Mesalazine.
DB14512
The risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Mesalazine.
DB14539
The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Mesalazine.
DB14541
The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone cypionate is combined with Mesalazine.
DB14545
The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Mesalazine.
DB14631
The risk or severity of gastrointestinal irritation can be increased when Prednisolone phosphate is combined with Mesalazine.
DB14633
The risk or severity of gastrointestinal irritation can be increased when Prednisolone hemisuccinate is combined with Mesalazine.
DB14644
The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Mesalazine.
DB14646
The risk or severity of gastrointestinal irritation can be increased when Prednisone acetate is combined with Mesalazine.
DB14652
The risk or severity of gastrointestinal irritation can be increased when Clocortolone acetate is combined with Mesalazine.
DB14659
The risk or severity of gastrointestinal irritation can be increased when Melengestrol acetate is combined with Mesalazine.
DB14669
The risk or severity of gastrointestinal irritation can be increased when Betamethasone phosphate is combined with Mesalazine.
DB01013
The risk or severity of gastrointestinal irritation can be increased when Clobetasol propionate is combined with Mesalazine.
DB01047
The risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Mesalazine.
DB14540
The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Mesalazine.
DB00547
The risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Mesalazine.
DB00764
The risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Mesalazine.
DB08971
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Mesalazine.
DB11750
The risk or severity of gastrointestinal irritation can be increased when Clobetasol is combined with Mesalazine.
DB15566
The risk or severity of gastrointestinal irritation can be increased when Prednisolone acetate is combined with Mesalazine.
DB00324
The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Mesalazine.
DB09095
The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Mesalazine.
DB00202
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mesalazine.
DB01026
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Ketoconazole.
DB01074
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Perhexiline.
DB01167
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Itraconazole.
DB01219
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Dantrolene.
DB02968
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Penicillin G Acyl-Serine.
DB06212
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Tolvaptan.
DB12097
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Mannitol busulfan.
DB00825
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Levomenthol.
DB00347
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Trimethadione.
DB00568
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Cinnarizine.
DB00593
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Ethosuximide.
DB00653
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Magnesium sulfate.
DB00836
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Loperamide.
DB01118
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Amiodarone.
DB04825
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Prenylamine.
DB04838
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Cyclandelate.
DB04841
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Flunarizine.
DB04842
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fluspirilene.
DB05246
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Methsuximide.
DB05885
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Seletracetam.
DB06152
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Nylidrin.
DB06446
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Dotarizine.
DB08838
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Agmatine.
DB08980
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fendiline.
DB08992
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Eperisone.
DB09090
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Pinaverium.
DB09227
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Barnidipine.
DB09229
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Aranidipine.
DB09230
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Azelnidipine.
DB09231
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Benidipine.
DB09232
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Cilnidipine.
DB09234
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Darodipine.
DB09240
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Niludipine.
DB11960
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Carboxyamidotriazole.
DB12131
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Vinpocetine.
DB12923
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Gallopamil.
DB13488
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Bencyclane.
DB13500
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Otilonium.
DB13725
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Terodiline.
DB13766
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Lidoflazine.
DB13791
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Penfluridol.
DB13835
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Caroverine.
DB13950
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with WIN 55212-2.
DB13961
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fish oil.
DB14063
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Dexverapamil.
DB14064
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Emopamil.
DB14065
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Lomerizine.
DB14066
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Tetrandrine.
DB09261
The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Certoparin.
DB10076
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Mesalazine.
DB10342
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Mesalazine.
DB10600
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) is combined with Mesalazine.
DB10794
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) is combined with Mesalazine.
DB10990
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Mesalazine.
DB11038
The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Mesalazine.
DB11040
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) is combined with Mesalazine.
DB11041
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Mesalazine.
DB11044
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Mesalazine.
DB14384
The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) is combined with Mesalazine.
DB14385
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Mesalazine.
DB14394
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen is combined with Mesalazine.
DB14445
The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) is combined with Mesalazine.
DB14449
The risk or severity of adverse effects can be increased when Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen is combined with Mesalazine.
DB14619
The risk or severity of adverse effects can be increased when Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) is combined with Mesalazine.
DB14620
The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) is combined with Mesalazine.
DB09413
The serum concentration of Mesalazine can be increased when it is combined with Monopotassium phosphate.
DB10318
The risk or severity of adverse effects can be increased when Mesalazine is combined with Varicella Zoster Vaccine (Live/attenuated).
DB09449
The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Mesalazine.
DB12364
The risk or severity of bleeding can be increased when Betrixaban is combined with Mesalazine.
DB01023
The therapeutic efficacy of Felodipine can be decreased when used in combination with Mesalazine.
DB00206
The therapeutic efficacy of Reserpine can be decreased when used in combination with Mesalazine.
DB00212
The therapeutic efficacy of Remikiren can be decreased when used in combination with Mesalazine.
DB00217
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mesalazine.
DB00226
The therapeutic efficacy of Guanadrel can be decreased when used in combination with Mesalazine.
DB00325
The therapeutic efficacy of Nitroprusside can be decreased when used in combination with Mesalazine.
DB00350
The therapeutic efficacy of Minoxidil can be decreased when used in combination with Mesalazine.
DB00457
The therapeutic efficacy of Prazosin can be decreased when used in combination with Mesalazine.
DB00559
The therapeutic efficacy of Bosentan can be decreased when used in combination with Mesalazine.
DB00575
The therapeutic efficacy of Clonidine can be decreased when used in combination with Mesalazine.
DB00590
The therapeutic efficacy of Doxazosin can be decreased when used in combination with Mesalazine.
DB00606
The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Mesalazine.
DB00616
The therapeutic efficacy of Candoxatril can be decreased when used in combination with Mesalazine.
DB00629
The therapeutic efficacy of Guanabenz can be decreased when used in combination with Mesalazine.
DB00657
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mesalazine.
DB00692
The therapeutic efficacy of Phentolamine can be decreased when used in combination with Mesalazine.
DB00727
The therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Mesalazine.
DB00765
The therapeutic efficacy of Metyrosine can be decreased when used in combination with Mesalazine.
DB00785
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Mesalazine.
DB00797
The therapeutic efficacy of Tolazoline can be decreased when used in combination with Mesalazine.
DB00800
The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Mesalazine.
DB00925
The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Mesalazine.
DB00968
The therapeutic efficacy of Methyldopa can be decreased when used in combination with Mesalazine.
DB01018
The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mesalazine.
DB01089
The therapeutic efficacy of Deserpidine can be decreased when used in combination with Mesalazine.
DB01090
The therapeutic efficacy of Pentolinium can be decreased when used in combination with Mesalazine.
DB01116
The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Mesalazine.
DB01119
The therapeutic efficacy of Diazoxide can be decreased when used in combination with Mesalazine.
DB01158
The therapeutic efficacy of Bretylium can be decreased when used in combination with Mesalazine.
DB01162
The therapeutic efficacy of Terazosin can be decreased when used in combination with Mesalazine.
DB01170
The therapeutic efficacy of Guanethidine can be decreased when used in combination with Mesalazine.
DB01626
The therapeutic efficacy of Pargyline can be decreased when used in combination with Mesalazine.
DB04831
The therapeutic efficacy of Tienilic acid can be decreased when used in combination with Mesalazine.
DB04840
The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Mesalazine.
DB04948
The therapeutic efficacy of Lofexidine can be decreased when used in combination with Mesalazine.
DB06268
The therapeutic efficacy of Sitaxentan can be decreased when used in combination with Mesalazine.
DB06403
The therapeutic efficacy of Ambrisentan can be decreased when used in combination with Mesalazine.
DB06445
The therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Mesalazine.
DB06762
The therapeutic efficacy of Pinacidil can be decreased when used in combination with Mesalazine.
DB08931
The therapeutic efficacy of Riociguat can be decreased when used in combination with Mesalazine.
DB08932
The therapeutic efficacy of Macitentan can be decreased when used in combination with Mesalazine.
DB08950
The therapeutic efficacy of Indoramin can be decreased when used in combination with Mesalazine.
DB08960
The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Mesalazine.
DB09206
The therapeutic efficacy of Trimazosin can be decreased when used in combination with Mesalazine.
DB09220
The therapeutic efficacy of Nicorandil can be decreased when used in combination with Mesalazine.
DB09242
The therapeutic efficacy of Moxonidine can be decreased when used in combination with Mesalazine.
DB09363
The therapeutic efficacy of Rauwolfia serpentina root can be decreased when used in combination with Mesalazine.
DB11362
The therapeutic efficacy of Selexipag can be decreased when used in combination with Mesalazine.
DB11720
The therapeutic efficacy of Angiotensin 1-7 can be decreased when used in combination with Mesalazine.
DB11738
The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Mesalazine.
DB12054
The therapeutic efficacy of BQ-123 can be decreased when used in combination with Mesalazine.
DB12661
The therapeutic efficacy of Urapidil can be decreased when used in combination with Mesalazine.
DB12766
The therapeutic efficacy of Cicletanine can be decreased when used in combination with Mesalazine.
DB12945
The therapeutic efficacy of Dihydralazine can be decreased when used in combination with Mesalazine.
DB13211
The therapeutic efficacy of Guanoxan can be decreased when used in combination with Mesalazine.
DB13374
The therapeutic efficacy of Vincamine can be decreased when used in combination with Mesalazine.
DB13410
The therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Mesalazine.
DB13429
The therapeutic efficacy of Tolonidine can be decreased when used in combination with Mesalazine.
DB13435
The therapeutic efficacy of Endralazine can be decreased when used in combination with Mesalazine.
DB13452
The therapeutic efficacy of Cadralazine can be decreased when used in combination with Mesalazine.
DB13575
The therapeutic efficacy of Bietaserpine can be decreased when used in combination with Mesalazine.
DB13604
The therapeutic efficacy of Guanazodine can be decreased when used in combination with Mesalazine.
DB13631
The therapeutic efficacy of Methoserpidine can be decreased when used in combination with Mesalazine.
DB13779
The therapeutic efficacy of Guanoclor can be decreased when used in combination with Mesalazine.
DB13801
The therapeutic efficacy of Muzolimine can be decreased when used in combination with Mesalazine.
DB13803
The therapeutic efficacy of Xipamide can be decreased when used in combination with Mesalazine.
DB00393
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Mesalazine.
DB00528
The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Mesalazine.
DB00622
The therapeutic efficacy of Nicardipine can be decreased when used in combination with Mesalazine.
DB01054
The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mesalazine.
DB01244
The therapeutic efficacy of Bepridil can be decreased when used in combination with Mesalazine.
DB01388
The therapeutic efficacy of Mibefradil can be decreased when used in combination with Mesalazine.
DB06712
The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Mesalazine.
DB09235
The therapeutic efficacy of Efonidipine can be decreased when used in combination with Mesalazine.
DB09236
The therapeutic efficacy of Lacidipine can be decreased when used in combination with Mesalazine.
DB09238
The therapeutic efficacy of Manidipine can be decreased when used in combination with Mesalazine.
DB09239
The therapeutic efficacy of Niguldipine can be decreased when used in combination with Mesalazine.
DB12093
The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Mesalazine.
DB14068
The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Mesalazine.
DB09237
The therapeutic efficacy of Levamlodipine can be decreased when used in combination with Mesalazine.
DB00091
The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Cyclosporine.
DB13615
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mesalazine.
DB11051
The risk or severity of adverse effects can be increased when Mesalazine is combined with Azficel-T.
DB11642
The risk or severity of adverse effects can be increased when Mesalazine is combined with Pitolisant.
DB00482
The risk or severity of adverse effects can be increased when Celecoxib is combined with Mesalazine.
DB00533
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Mesalazine.
DB00580
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Mesalazine.
DB00936
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Mesalazine.
DB01050
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Mesalazine.
DB01283
The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Mesalazine.
DB01628
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Mesalazine.
DB03585
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mesalazine.
DB04552
The risk or severity of adverse effects can be increased when Niflumic acid is combined with Mesalazine.
DB04812
The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mesalazine.
DB04817
The risk or severity of adverse effects can be increased when Metamizole is combined with Mesalazine.
DB04828
The risk or severity of adverse effects can be increased when Zomepirac is combined with Mesalazine.
DB06737
The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mesalazine.
DB07402
The risk or severity of adverse effects can be increased when Azapropazone is combined with Mesalazine.
DB07477
The risk or severity of adverse effects can be increased when Felbinac is combined with Mesalazine.
DB08439
The risk or severity of adverse effects can be increased when Parecoxib is combined with Mesalazine.
DB08797
The risk or severity of adverse effects can be increased when Salicylamide is combined with Mesalazine.
DB08940
The risk or severity of adverse effects can be increased when Kebuzone is combined with Mesalazine.
DB08942
The risk or severity of adverse effects can be increased when Isoxicam is combined with Mesalazine.
DB08951
The risk or severity of adverse effects can be increased when Indoprofen is combined with Mesalazine.
DB08955
The risk or severity of adverse effects can be increased when Ibuproxam is combined with Mesalazine.
DB08976
The risk or severity of adverse effects can be increased when Floctafenine is combined with Mesalazine.
DB08981
The risk or severity of adverse effects can be increased when Fenbufen is combined with Mesalazine.
DB08984
The risk or severity of adverse effects can be increased when Etofenamate is combined with Mesalazine.
DB08991
The risk or severity of adverse effects can be increased when Epirizole is combined with Mesalazine.
DB09212
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Mesalazine.
DB09216
The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Mesalazine.
DB09218
The risk or severity of adverse effects can be increased when Clonixin is combined with Mesalazine.
DB11466
The risk or severity of adverse effects can be increased when Tepoxalin is combined with Mesalazine.
DB11518
The risk or severity of adverse effects can be increased when Flunixin is combined with Mesalazine.
DB13001
The risk or severity of adverse effects can be increased when Tinoridine is combined with Mesalazine.
DB13167
The risk or severity of adverse effects can be increased when Alclofenac is combined with Mesalazine.
DB13217
The risk or severity of adverse effects can be increased when Fentiazac is combined with Mesalazine.
DB13232
The risk or severity of adverse effects can be increased when Suxibuzone is combined with Mesalazine.
DB13286
The risk or severity of adverse effects can be increased when Bumadizone is combined with Mesalazine.
DB13314
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Mesalazine.
DB13364
The risk or severity of adverse effects can be increased when Feprazone is combined with Mesalazine.
DB13371
The risk or severity of adverse effects can be increased when Difenpiramide is combined with Mesalazine.
DB13407
The risk or severity of adverse effects can be increased when Nifenazone is combined with Mesalazine.
DB13432
The risk or severity of adverse effects can be increased when Lonazolac is combined with Mesalazine.
DB13481
The risk or severity of adverse effects can be increased when Tenidap is combined with Mesalazine.
DB13501
The risk or severity of adverse effects can be increased when Bendazac is combined with Mesalazine.
DB13514
The risk or severity of adverse effects can be increased when Pranoprofen is combined with Mesalazine.
DB13524
The risk or severity of adverse effects can be increased when Propyphenazone is combined with Mesalazine.
DB13527
The risk or severity of adverse effects can be increased when Proglumetacin is combined with Mesalazine.
DB13544
The risk or severity of adverse effects can be increased when Ethenzamide is combined with Mesalazine.
DB13629
The risk or severity of adverse effects can be increased when Mofebutazone is combined with Mesalazine.
DB13649
The risk or severity of adverse effects can be increased when Proquazone is combined with Mesalazine.
DB13657
The risk or severity of adverse effects can be increased when Benorilate is combined with Mesalazine.
DB13722
The risk or severity of adverse effects can be increased when Pirprofen is combined with Mesalazine.
DB13783
The risk or severity of adverse effects can be increased when Acemetacin is combined with Mesalazine.
DB13860
The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Mesalazine.
DB09084
The risk or severity of adverse effects can be increased when Benzydamine is combined with Mesalazine.
DB05095
The risk or severity of adverse effects can be increased when Cimicoxib is combined with Mesalazine.
DB11455
The risk or severity of adverse effects can be increased when Robenacoxib is combined with Mesalazine.
DB01424
The risk or severity of adverse effects can be increased when Aminophenazone is combined with Mesalazine.
DB14059
The risk or severity of adverse effects can be increased when Mesalazine is combined with SC-236.
DB14060
The risk or severity of adverse effects can be increased when Mesalazine is combined with NS-398.
DB09217
The risk or severity of adverse effects can be increased when Mesalazine is combined with Firocoxib.
DB09285
The risk or severity of adverse effects can be increased when Mesalazine is combined with Morniflumate.
DB09295
The risk or severity of adverse effects can be increased when Mesalazine is combined with Talniflumate.
DB02224
The risk or severity of adverse effects can be increased when Mesalazine is combined with Taxifolin.
DB12480
The risk or severity of adverse effects can be increased when Mesalazine is combined with Betulinic Acid.
DB12610
The risk or severity of adverse effects can be increased when Mesalazine is combined with Ebselen.
DB14938
The risk or severity of adverse effects can be increased when Mesalazine is combined with Flurbiprofen axetil.
DB12399
The risk or severity of adverse effects can be increased when Mesalazine is combined with Polmacoxib.
DB04725
The risk or severity of adverse effects can be increased when Mesalazine is combined with Licofelone.
DB04743
The risk or severity of adverse effects can be increased when Mesalazine is combined with Nimesulide.
DB12545
The risk or severity of adverse effects can be increased when Mesalazine is combined with Indobufen.
DB00007
Mesalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00014
Mesalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00017
Mesalazine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00041
Mesalazine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00080
Mesalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
DB00081
Mesalazine may decrease the excretion rate of Tositumomab which could result in a higher serum level.
DB00115
Mesalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
DB00158
Mesalazine may decrease the excretion rate of Folic acid which could result in a higher serum level.
DB00165
Mesalazine may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
DB00182
Mesalazine may decrease the excretion rate of Amphetamine which could result in a higher serum level.
DB00185
Mesalazine may decrease the excretion rate of Cevimeline which could result in a higher serum level.
DB00186
Mesalazine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00190
Mesalazine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00193
Mesalazine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00196
Mesalazine may decrease the excretion rate of Fluconazole which could result in a higher serum level.
DB00198
Mesalazine may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00200
Mesalazine may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00225
Mesalazine may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00230
Mesalazine may decrease the excretion rate of Pregabalin which could result in a higher serum level.
DB00231
Mesalazine may decrease the excretion rate of Temazepam which could result in a higher serum level.
DB00235
Mesalazine may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00237
Mesalazine may decrease the excretion rate of Butabarbital which could result in a higher serum level.
DB00243
Mesalazine may decrease the excretion rate of Ranolazine which could result in a higher serum level.
DB00245
Mesalazine may decrease the excretion rate of Benzatropine which could result in a higher serum level.
DB00254
Mesalazine may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00262
Mesalazine may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00271
Mesalazine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00273
Mesalazine may decrease the excretion rate of Topiramate which could result in a higher serum level.
DB00279
Mesalazine may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00286
Mesalazine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00289
Mesalazine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
DB00290
Mesalazine may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00292
Mesalazine may decrease the excretion rate of Etomidate which could result in a higher serum level.
DB00294
Mesalazine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00296
Mesalazine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00303
Mesalazine may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00308
Mesalazine may decrease the excretion rate of Ibutilide which could result in a higher serum level.
DB00312
Mesalazine may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
DB00319
Mesalazine may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00322
Mesalazine may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00323
Mesalazine may decrease the excretion rate of Tolcapone which could result in a higher serum level.
DB00327
Mesalazine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
DB00330
Mesalazine may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00333
Mesalazine may decrease the excretion rate of Methadone which could result in a higher serum level.
DB00339
Mesalazine may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00341
Mesalazine may decrease the excretion rate of Cetirizine which could result in a higher serum level.
DB00349
Mesalazine may decrease the excretion rate of Clobazam which could result in a higher serum level.
DB00351
Mesalazine may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00355
Mesalazine may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00356
Mesalazine may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
DB00363
Mesalazine may decrease the excretion rate of Clozapine which could result in a higher serum level.
DB00364
Mesalazine may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00369
Mesalazine may decrease the excretion rate of Cidofovir which could result in a higher serum level.
DB00372
Mesalazine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
DB00377
Mesalazine may decrease the excretion rate of Palonosetron which could result in a higher serum level.
DB00380
Mesalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00398
Mesalazine may decrease the excretion rate of Sorafenib which could result in a higher serum level.
DB00402
Mesalazine may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
DB00404
Mesalazine may decrease the excretion rate of Alprazolam which could result in a higher serum level.
DB00413
Mesalazine may decrease the excretion rate of Pramipexole which could result in a higher serum level.
DB00415
Mesalazine may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00418
Mesalazine may decrease the excretion rate of Secobarbital which could result in a higher serum level.
DB00422
Mesalazine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
DB00432
Mesalazine may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00435
Mesalazine may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
DB00437
Mesalazine may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00438
Mesalazine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.
DB00440
Mesalazine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00441
Mesalazine may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00477
Mesalazine may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
DB00480
Mesalazine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00490
Mesalazine may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00499
Mesalazine may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00535
Mesalazine may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00537
Mesalazine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
DB00548
Mesalazine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00553
Mesalazine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00558
Mesalazine may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00567
Mesalazine may decrease the excretion rate of Cephalexin which could result in a higher serum level.
DB00577
Mesalazine may decrease the excretion rate of Valaciclovir which could result in a higher serum level.
DB00583
Mesalazine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00597
Mesalazine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00603
Mesalazine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
DB00608
Mesalazine may decrease the excretion rate of Chloroquine which could result in a higher serum level.
DB00624
Mesalazine may decrease the excretion rate of Testosterone which could result in a higher serum level.
DB00628
Mesalazine may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
DB00631
Mesalazine may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00633
Mesalazine may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
DB00651
Mesalazine may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00660
Mesalazine may decrease the excretion rate of Metaxalone which could result in a higher serum level.
DB00665
Mesalazine may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00669
Mesalazine may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
DB00683
Mesalazine may decrease the excretion rate of Midazolam which could result in a higher serum level.
DB00688
Mesalazine may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
DB00690
Mesalazine may decrease the excretion rate of Flurazepam which could result in a higher serum level.
DB00698
Mesalazine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00706
Mesalazine may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00709
Mesalazine may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00713
Mesalazine may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00716
Mesalazine may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00730
Mesalazine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00733
Mesalazine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00743
Mesalazine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
DB00759
Mesalazine may decrease the excretion rate of Tetracycline which could result in a higher serum level.
DB00760
Mesalazine may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00761
Mesalazine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00763
Mesalazine may decrease the excretion rate of Methimazole which could result in a higher serum level.
DB00780
Mesalazine may decrease the excretion rate of Phenelzine which could result in a higher serum level.
DB00782
Mesalazine may decrease the excretion rate of Propantheline which could result in a higher serum level.
DB00783
Mesalazine may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB00787
Mesalazine may decrease the excretion rate of Acyclovir which could result in a higher serum level.
DB00789
Mesalazine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00804
Mesalazine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
DB00811
Mesalazine may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00820
Mesalazine may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB00828
Mesalazine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00829
Mesalazine may decrease the excretion rate of Diazepam which could result in a higher serum level.
DB00833
Mesalazine may decrease the excretion rate of Cefaclor which could result in a higher serum level.
DB00841
Mesalazine may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00842
Mesalazine may decrease the excretion rate of Oxazepam which could result in a higher serum level.
DB00851
Mesalazine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00853
Mesalazine may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00871
Mesalazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.
DB00894
Mesalazine may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00897
Mesalazine may decrease the excretion rate of Triazolam which could result in a higher serum level.
DB00900
Mesalazine may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00911
Mesalazine may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00915
Mesalazine may decrease the excretion rate of Amantadine which could result in a higher serum level.
DB00918
Mesalazine may decrease the excretion rate of Almotriptan which could result in a higher serum level.
DB00928
Mesalazine may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00934
Mesalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
DB00951
Mesalazine may decrease the excretion rate of Isoniazid which could result in a higher serum level.
DB00953
Mesalazine may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
DB00958
Mesalazine may decrease the excretion rate of Carboplatin which could result in a higher serum level.
DB00961
Mesalazine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00962
Mesalazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.
DB00980
Mesalazine may decrease the excretion rate of Ramelteon which could result in a higher serum level.
DB00988
Mesalazine may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00993
Mesalazine may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00995
Mesalazine may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB01001
Mesalazine may decrease the excretion rate of Salbutamol which could result in a higher serum level.
DB01002
Mesalazine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB01004
Mesalazine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
DB01010
Mesalazine may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB01011
Mesalazine may decrease the excretion rate of Metyrapone which could result in a higher serum level.
DB01020
Mesalazine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB01022
Mesalazine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB01024
Mesalazine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB01030
Mesalazine may decrease the excretion rate of Topotecan which could result in a higher serum level.
DB01036
Mesalazine may decrease the excretion rate of Tolterodine which could result in a higher serum level.
DB01039
Mesalazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
DB01043
Mesalazine may decrease the excretion rate of Memantine which could result in a higher serum level.
DB01046
Mesalazine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB01048
Mesalazine may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB01060
Mesalazine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB01068
Mesalazine may decrease the excretion rate of Clonazepam which could result in a higher serum level.
DB01093
Mesalazine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
DB01099
Mesalazine may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB01101
Mesalazine may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB01135
Mesalazine may decrease the excretion rate of Doxacurium which could result in a higher serum level.
DB01137
Mesalazine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
DB01140
Mesalazine may decrease the excretion rate of Cefadroxil which could result in a higher serum level.
DB01148
Mesalazine may decrease the excretion rate of Flavoxate which could result in a higher serum level.
DB01156
Mesalazine may decrease the excretion rate of Bupropion which could result in a higher serum level.
DB01157
Mesalazine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB01169
Mesalazine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
DB01181
Mesalazine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
DB01183
Mesalazine may decrease the excretion rate of Naloxone which could result in a higher serum level.
DB01205
Mesalazine may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB01212
Mesalazine may decrease the excretion rate of Ceftriaxone which could result in a higher serum level.
DB01213
Mesalazine may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB01215
Mesalazine may decrease the excretion rate of Estazolam which could result in a higher serum level.
DB01221
Mesalazine may decrease the excretion rate of Ketamine which could result in a higher serum level.
DB01224
Mesalazine may decrease the excretion rate of Quetiapine which could result in a higher serum level.
DB01233
Mesalazine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
DB01241
Mesalazine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
DB01249
Mesalazine may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB01267
Mesalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
DB01273
Mesalazine may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB01274
Mesalazine may decrease the excretion rate of Arformoterol which could result in a higher serum level.
DB01330
Mesalazine may decrease the excretion rate of Cefotetan which could result in a higher serum level.
DB01333
Mesalazine may decrease the excretion rate of Cefradine which could result in a higher serum level.
DB01367
Mesalazine may decrease the excretion rate of Rasagiline which could result in a higher serum level.
DB01394
Mesalazine may decrease the excretion rate of Colchicine which could result in a higher serum level.
DB01409
Mesalazine may decrease the excretion rate of Tiotropium which could result in a higher serum level.
DB01415
Mesalazine may decrease the excretion rate of Ceftibuten which could result in a higher serum level.
DB01420
Mesalazine may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB01427
Mesalazine may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB01428
Mesalazine may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB01431
Mesalazine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
DB01550
Mesalazine may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB01558
Mesalazine may decrease the excretion rate of Bromazepam which could result in a higher serum level.
DB01563
Mesalazine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
DB01577
Mesalazine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
DB01587
Mesalazine may decrease the excretion rate of Ketazolam which could result in a higher serum level.
DB01610
Mesalazine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB01638
Mesalazine may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB01656
Mesalazine may decrease the excretion rate of Roflumilast which could result in a higher serum level.
DB01685
Mesalazine may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
DB04574
Mesalazine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB04871
Mesalazine may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
DB04895
Mesalazine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB04953
Mesalazine may decrease the excretion rate of Ezogabine which could result in a higher serum level.
DB05018
Mesalazine may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB05541
Mesalazine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
DB05676
Mesalazine may decrease the excretion rate of Apremilast which could result in a higher serum level.
DB06154
Mesalazine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB06186
Mesalazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB06196
Mesalazine may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB06211
Mesalazine may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB06230
Mesalazine may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB06262
Mesalazine may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB06282
Mesalazine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
DB06402
Mesalazine may decrease the excretion rate of Telavancin which could result in a higher serum level.
DB06480
Mesalazine may decrease the excretion rate of Prucalopride which could result in a higher serum level.
DB06623
Mesalazine may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB06637
Mesalazine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB06702
Mesalazine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
DB06705
Mesalazine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB06710
Mesalazine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB06782
Mesalazine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB06796
Mesalazine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB06800
Mesalazine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB06809
Mesalazine may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB06823
Mesalazine may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB06824
Mesalazine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB08824
Mesalazine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB08826
Mesalazine may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB08840
Mesalazine may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB08872
Mesalazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
DB08877
Mesalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DB08893
Mesalazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
DB08894
Mesalazine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
DB08897
Mesalazine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
DB08899
Mesalazine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
DB08900
Mesalazine may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB08904
Mesalazine may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
DB08905
Mesalazine may decrease the excretion rate of Formestane which could result in a higher serum level.
DB08909
Mesalazine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
DB08910
Mesalazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
DB08911
Mesalazine may decrease the excretion rate of Trametinib which could result in a higher serum level.
DB08934
Mesalazine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB09027
Mesalazine may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB09050
Mesalazine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB09066
Mesalazine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
DB09068
Mesalazine may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
DB09071
Mesalazine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
DB09081
Mesalazine may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB09082
Mesalazine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
DB09103
Mesalazine may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB09106
Mesalazine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB09111
Mesalazine may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB09118
Mesalazine may decrease the excretion rate of Stiripentol which could result in a higher serum level.
DB09121
Mesalazine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB09123
Mesalazine may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB09129
Mesalazine may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB09132
Mesalazine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB09133
Mesalazine may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB09134
Mesalazine may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB09135
Mesalazine may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB09136
Mesalazine may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB09137
Mesalazine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB09139
Mesalazine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB09148
Mesalazine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB09149
Mesalazine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB09156
Mesalazine may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB09163
Mesalazine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB09165
Mesalazine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB09185
Mesalazine may decrease the excretion rate of Viloxazine which could result in a higher serum level.
DB09194
Mesalazine may decrease the excretion rate of Etoperidone which could result in a higher serum level.
DB09195
Mesalazine may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
DB09205
Mesalazine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB09209
Mesalazine may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB09210
Mesalazine may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB09219
Mesalazine may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB09223
Mesalazine may decrease the excretion rate of Blonanserin which could result in a higher serum level.
DB09224
Mesalazine may decrease the excretion rate of Melperone which could result in a higher serum level.
DB09241
Mesalazine may decrease the excretion rate of Methylene blue which could result in a higher serum level.
DB09244
Mesalazine may decrease the excretion rate of Pirlindole which could result in a higher serum level.
DB09245
Mesalazine may decrease the excretion rate of Toloxatone which could result in a higher serum level.
DB09256
Mesalazine may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB09257
Mesalazine may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB09262
Mesalazine may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
DB09264
Mesalazine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB09268
Mesalazine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB09276
Mesalazine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB09277
Mesalazine may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
DB09292
Mesalazine may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB09301
Mesalazine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB09317
Mesalazine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB09318
Mesalazine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB09320
Mesalazine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB09324
Mesalazine may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB09325
Mesalazine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB09329
Mesalazine may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB09338
Mesalazine may decrease the excretion rate of Mersalyl which could result in a higher serum level.
DB09344
Mesalazine may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB09357
Mesalazine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB09394
Mesalazine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB09395
Mesalazine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB09407
Mesalazine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB09418
Mesalazine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB09472
Mesalazine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB09488
Mesalazine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
DB09496
Mesalazine may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB09502
Mesalazine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB09546
Mesalazine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB09570
Mesalazine may decrease the excretion rate of Ixazomib which could result in a higher serum level.
DB11077
Mesalazine may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB11090
Mesalazine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB11098
Mesalazine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB11102
Mesalazine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB11114
Mesalazine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB11127
Mesalazine may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB11130
Mesalazine may decrease the excretion rate of Opium which could result in a higher serum level.
DB11135
Mesalazine may decrease the excretion rate of Selenium which could result in a higher serum level.
DB11136
Mesalazine may decrease the excretion rate of Chromium which could result in a higher serum level.
DB11145
Mesalazine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB11156
Mesalazine may decrease the excretion rate of Pyrantel which could result in a higher serum level.
DB11164
Mesalazine may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB11251
Mesalazine may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB11278
Mesalazine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB11328
Mesalazine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB11338
Mesalazine may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB11358
Mesalazine may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB11364
Mesalazine may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB11367
Mesalazine may decrease the excretion rate of Cefroxadine which could result in a higher serum level.
DB11560
Mesalazine may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB11577
Mesalazine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB11587
Mesalazine may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB11691
Mesalazine may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB11699
Mesalazine may decrease the excretion rate of Tropisetron which could result in a higher serum level.
DB11817
Mesalazine may decrease the excretion rate of Baricitinib which could result in a higher serum level.
DB11901
Mesalazine may decrease the excretion rate of Apalutamide which could result in a higher serum level.
DB11915
Mesalazine may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB11943
Mesalazine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
DB11989
Mesalazine may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB12007
Mesalazine may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB12107
Mesalazine may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB12151
Mesalazine may decrease the excretion rate of Brincidofovir which could result in a higher serum level.
DB12161
Mesalazine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
DB12278
Mesalazine may decrease the excretion rate of Propiverine which could result in a higher serum level.
DB12783
Mesalazine may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB13025
Mesalazine may decrease the excretion rate of Tiapride which could result in a higher serum level.
DB13139
Mesalazine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB13156
Mesalazine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB13178
Mesalazine may decrease the excretion rate of Inositol which could result in a higher serum level.
DB13185
Mesalazine may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB13191
Mesalazine may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB13269
Mesalazine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB13293
Mesalazine may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB13873
Mesalazine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB13884
Mesalazine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB13909
Mesalazine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB13943
Mesalazine may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
DB13944
Mesalazine may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
DB13952
Mesalazine may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
DB13954
Mesalazine may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
DB13955
Mesalazine may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
DB13956
Mesalazine may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
DB13967
Mesalazine may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB14007
Mesalazine may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB14498
Mesalazine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB14499
Mesalazine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB14526
Mesalazine may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB14527
Mesalazine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB14528
Mesalazine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB14529
Mesalazine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB14530
Mesalazine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB06815
Mesalazine may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB11121
Mesalazine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB11085
Mesalazine may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB00270
Mesalazine may decrease the excretion rate of Isradipine which could result in a higher serum level.
DB00401
Mesalazine may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
DB00555
Mesalazine may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
DB01115
Mesalazine may decrease the excretion rate of Nifedipine which could result in a higher serum level.
DB04920
Mesalazine may decrease the excretion rate of Clevidipine which could result in a higher serum level.
DB09089
Mesalazine may decrease the excretion rate of Trimebutine which could result in a higher serum level.
DB15593
Mesalazine may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00321
Mesalazine may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
DB00458
Mesalazine may decrease the excretion rate of Imipramine which could result in a higher serum level.
DB00813
Mesalazine may decrease the excretion rate of Fentanyl which could result in a higher serum level.
DB01151
Mesalazine may decrease the excretion rate of Desipramine which could result in a higher serum level.
DB01242
Mesalazine may decrease the excretion rate of Clomipramine which could result in a higher serum level.
DB08996
Mesalazine may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
DB00318
Mesalazine may decrease the excretion rate of Codeine which could result in a higher serum level.
DB00454
Mesalazine may decrease the excretion rate of Meperidine which could result in a higher serum level.
DB00879
Mesalazine may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB13987
Mesalazine may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
DB01345
Mesalazine may decrease the excretion rate of Potassium cation which could result in a higher serum level.
DB04890
Mesalazine may decrease the excretion rate of Bepotastine which could result in a higher serum level.
DB00982
Mesalazine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB04930
Mesalazine may decrease the excretion rate of Permethrin which could result in a higher serum level.
DB00479
Mesalazine may decrease the excretion rate of Amikacin which could result in a higher serum level.
DB00684
Mesalazine may decrease the excretion rate of Tobramycin which could result in a higher serum level.
DB00798
Mesalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.
DB00955
Mesalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.
DB01082
Mesalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.
DB01172
Mesalazine may decrease the excretion rate of Kanamycin which could result in a higher serum level.
DB03615
Mesalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
DB04729
Mesalazine may decrease the excretion rate of Gentamicin C1a which could result in a higher serum level.
DB06696
Mesalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.
DB12604
Mesalazine may decrease the excretion rate of Sisomicin which could result in a higher serum level.
DB13540
Mesalazine may decrease the excretion rate of Isepamicin which could result in a higher serum level.
DB00314
Mesalazine may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00515
Mesalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
DB00564
Mesalazine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
DB00908
Mesalazine may decrease the excretion rate of Quinidine which could result in a higher serum level.
DB01035
Mesalazine may decrease the excretion rate of Procainamide which could result in a higher serum level.
DB12615
Mesalazine may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00552
Mesalazine may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB13145
Mesalazine may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00803
Mesalazine may decrease the excretion rate of Colistin which could result in a higher serum level.
DB09087
Potassium alum may increase the hyperkalemic activities of Mesalazine.
DB09414
Dipotassium phosphate may increase the hyperkalemic activities of Mesalazine.
DB09483
Potassium lactate may increase the hyperkalemic activities of Mesalazine.
DB11107
Potassium bitartrate may increase the hyperkalemic activities of Mesalazine.
DB11153
Potassium hydroxide may increase the hyperkalemic activities of Mesalazine.
DB13620
Potassium gluconate may increase the hyperkalemic activities of Mesalazine.
DB13735
Potassium guaiacolsulfonate may increase the hyperkalemic activities of Mesalazine.
DB13831
Potassium permanganate may increase the hyperkalemic activities of Mesalazine.
DB13977
Potassium carbonate may increase the hyperkalemic activities of Mesalazine.
DB14492
Potassium triiodide may increase the hyperkalemic activities of Mesalazine.
DB14500
Potassium may increase the hyperkalemic activities of Mesalazine.
DB06715
Potassium Iodide may increase the hyperkalemic activities of Mesalazine.
DB00252
The serum concentration of Phenytoin can be increased when it is combined with Mesalazine.
DB00581
Lactulose can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13074
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Mesalazine.
DB00024
The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Mesalazine.
DB00451
The therapeutic efficacy of Levothyroxine can be increased when used in combination with Mesalazine.
DB01583
The therapeutic efficacy of Liotrix can be increased when used in combination with Mesalazine.
DB03604
The therapeutic efficacy of Tiratricol can be increased when used in combination with Mesalazine.
DB09100
The therapeutic efficacy of Thyroid, porcine can be increased when used in combination with Mesalazine.
DB11823
The risk or severity of hypertension can be increased when Esketamine is combined with Mesalazine.
DB00781
The risk or severity of adverse effects can be increased when Mesalazine is combined with Polymyxin B.
DB14754
The risk or severity of hypertension can be increased when Solriamfetol is combined with Mesalazine.
DB00316
The risk or severity of adverse effects can be increased when Acetaminophen is combined with Mesalazine.
DB09288
The risk or severity of adverse effects can be increased when Propacetamol is combined with Mesalazine.
DB13946
Testosterone undecanoate may increase the hypertensive activities of Mesalazine.
DB00181
Mesalazine may decrease the excretion rate of Baclofen which could result in a higher serum level.
DB00898
The risk or severity of gastrointestinal irritation can be increased when Ethanol is combined with Mesalazine.
DB00495
The risk or severity of bleeding can be increased when Zidovudine is combined with Mesalazine.
DB00063
The risk or severity of bleeding can be increased when Mesalazine is combined with Eptifibatide.
DB00208
The risk or severity of bleeding can be increased when Mesalazine is combined with Ticlopidine.
DB00758
The risk or severity of bleeding can be increased when Mesalazine is combined with Clopidogrel.
DB00775
The risk or severity of bleeding can be increased when Mesalazine is combined with Tirofiban.
DB00806
The risk or severity of bleeding can be increased when Mesalazine is combined with Pentoxifylline.
DB01138
The risk or severity of bleeding can be increased when Mesalazine is combined with Sulfinpyrazone.
DB01166
The risk or severity of bleeding can be increased when Mesalazine is combined with Cilostazol.
DB01207
The risk or severity of bleeding can be increased when Mesalazine is combined with Ridogrel.
DB01236
The risk or severity of bleeding can be increased when Mesalazine is combined with Sevoflurane.
DB02709
The risk or severity of bleeding can be increased when Mesalazine is combined with Resveratrol.
DB04905
The risk or severity of bleeding can be increased when Mesalazine is combined with Tesmilifene.
DB05266
The risk or severity of bleeding can be increased when Mesalazine is combined with Ibudilast.
DB05767
The risk or severity of bleeding can be increased when Mesalazine is combined with Andrographolide.
DB06081
The risk or severity of bleeding can be increased when Mesalazine is combined with Caplacizumab.
DB07615
The risk or severity of bleeding can be increased when Mesalazine is combined with Tranilast.
DB08887
The risk or severity of bleeding can be increased when Mesalazine is combined with Icosapent ethyl.
DB09283
The risk or severity of bleeding can be increased when Mesalazine is combined with Trapidil.
DB12092
The risk or severity of bleeding can be increased when Mesalazine is combined with Naftopidil.
DB12163
The risk or severity of bleeding can be increased when Mesalazine is combined with Sarpogrelate.
DB12321
The risk or severity of bleeding can be increased when Mesalazine is combined with Ifetroban.
DB12465
The risk or severity of bleeding can be increased when Mesalazine is combined with Ketanserin.
DB12749
The risk or severity of bleeding can be increased when Mesalazine is combined with Butylphthalide.
DB12771
The risk or severity of bleeding can be increased when Mesalazine is combined with Hydroxytyrosol.
DB13036
The risk or severity of bleeding can be increased when Mesalazine is combined with Ramatroban.
DB13327
The risk or severity of bleeding can be increased when Mesalazine is combined with Picotamide.
DB13367
The risk or severity of bleeding can be increased when Mesalazine is combined with Cloricromen.
DB13400
The risk or severity of bleeding can be increased when Mesalazine is combined with Linsidomine.
DB13510
The risk or severity of bleeding can be increased when Mesalazine is combined with Buflomedil.
DB13929
The risk or severity of bleeding can be increased when Mesalazine is combined with Relcovaptan.
DB00261
The risk or severity of bleeding can be increased when Anagrelide is combined with Mesalazine.
DB00695
The risk or severity of adverse effects can be increased when Mesalazine is combined with Furosemide.
DB01104
The risk or severity of bleeding can be increased when Sertraline is combined with Mesalazine.
DB01320
The protein binding of Fosphenytoin can be decreased when combined with Mesalazine.
DB00869
The risk or severity of metabolic acidosis can be increased when Dorzolamide is combined with Mesalazine.
DB00994
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neomycin.
DB00465
The risk or severity of adverse effects can be increased when Ketorolac is combined with Mesalazine.
序列
实验性质
Water Solubility
0.84 g/L at 20°C

Melting Point
283 °C
PhysProp
logP
1.2

外部标识符
resource:Drugs Product Database (DPD)
identifier:14088
resource:ChEBI
identifier:6775
resource:PubChem Compound
identifier:4075
resource:PubChem Substance
identifier:46509142
resource:KEGG Drug
identifier:D00377
resource:ChemSpider
identifier:3933
resource:BindingDB
identifier:60918
resource:PharmGKB
identifier:PA450384
resource:Therapeutic Targets Database
identifier:DAP000729
resource:IUPHAR
identifier:2700
resource:Guide to Pharmacology
identifier:2700
resource:Wikipedia
identifier:Mesalazine
resource:ChEMBL
identifier:CHEMBL704
resource:ZINC
identifier:ZINC000000001688
resource:RxCUI
identifier:52582
外部链接
RxList
http://www.rxlist.com/cgi/generic2/canasa.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/row1389.shtml
路径
目标
id:BE0000262
name:Prostaglandin G/H synthase 2
organism:Humans
action:inhibitor
Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.
Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.
Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19.
Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6.
Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7.
known-action:yes
name:Prostaglandin G/H synthase 2
general-function:Prostaglandin-endoperoxide synthase activity
specific-function:Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.
gene-name:PTGS2
locus:1q25.2-q25.3
cellular-location:Microsome membrane
transmembrane-regions:
signal-regions:1-17
theoretical-pi:7.41
molecular-weight:68995.625
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:9605GenAtlasPTGS2GenBank Gene DatabaseL15326GenBank Protein Database291988Guide to Pharmacology1376UniProtKBP35354UniProt AccessionPGH2_HUMAN
synonyms:1.14.99.1COX-2COX2Cyclooxygenase-2PGH synthase 2PGHS-2PHS IIProstaglandin H2 synthase 2Prostaglandin-endoperoxide synthase 2
amino-acid-sequence:>lcl|BSEQ0021832|Prostaglandin G/H synthase 2 MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER STEL
gene-sequence:>lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2) ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT TCGACTGAACTGTAG
pfams:PF03098An_peroxidasePF00008EGF
go-classifiers:componentcaveolacomponentcytoplasmcomponentendoplasmic reticulumcomponentendoplasmic reticulum lumencomponentendoplasmic reticulum membranecomponentneuron projectioncomponentnucleuscomponentprotein complexfunctionarachidonate 15-lipoxygenase activityfunctionenzyme bindingfunctionheme bindingfunctionlipid bindingfunctionmetal ion bindingfunctionperoxidase activityfunctionprostaglandin-endoperoxide synthase activityprocessangiogenesisprocessarachidonic acid metabolic processprocessbone mineralizationprocessbrown fat cell differentiationprocesscellular response to ATPprocesscellular response to fluid shear stressprocesscellular response to hypoxiaprocesscellular response to mechanical stimulusprocesscellular response to UVprocesscyclooxygenase pathwayprocessdecidualizationprocessembryo implantationprocesshair cycleprocessinflammatory responseprocesslearningprocesslipoxygenase pathwayprocessmaintenance of blood-brain barrierprocessmemoryprocessmovement of cell or subcellular componentprocessNAD metabolic processprocessnegative regulation of calcium ion transportprocessnegative regulation of cell cycleprocessnegative regulation of cell proliferationprocessnegative regulation of smooth muscle contractionprocessnegative regulation of synaptic transmission, dopaminergicprocessnicotinamide metabolic processprocessovulationprocesspositive regulation of apoptotic processprocesspositive regulation of brown fat cell differentiationprocesspositive regulation of cell migration involved in sprouting angiogenesisprocesspositive regulation of fever generationprocesspositive regulation of fibroblast growth factor productionprocesspositive regulation of NF-kappaB import into nucleusprocesspositive regulation of nitric oxide biosynthetic processprocesspositive regulation of platelet-derived growth factor productionprocesspositive regulation of prostaglandin biosynthetic processprocesspositive regulation of smooth muscle cell proliferationprocesspositive regulation of smooth muscle contractionprocesspositive regulation of synaptic plasticityprocesspositive regulation of synaptic transmission, glutamatergicprocesspositive regulation of transforming growth factor beta productionprocesspositive regulation of vascular endothelial growth factor productionprocesspositive regulation of vasoconstrictionprocessprostaglandin biosynthetic processprocessprostaglandin metabolic processprocessregulation of blood pressureprocessregulation of inflammatory responseprocessresponse to drugprocessresponse to estradiolprocessresponse to fatty acidprocessresponse to fructoseprocessresponse to glucocorticoidprocessresponse to lipopolysaccharideprocessresponse to lithium ionprocessresponse to manganese ionprocessresponse to oxidative stressprocessresponse to tumor necrosis factorprocessresponse to vitamin Dprocesssensory perception of painprocesssmall molecule metabolic processprocessvitamin metabolic processprocesswater-soluble vitamin metabolic process
id:BE0000017
name:Prostaglandin G/H synthase 1
organism:Humans
action:inhibitor
Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
known-action:yes
name:Prostaglandin G/H synthase 1
general-function:Prostaglandin-endoperoxide synthase activity
specific-function:Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells.
gene-name:PTGS1
locus:9q32-q33.3
cellular-location:Microsome membrane
transmembrane-regions:
signal-regions:1-23
theoretical-pi:7.39
molecular-weight:68685.82
chromosome-location:9
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:9604GenAtlasPTGS1GenBank Gene DatabaseM31822GenBank Protein Database387018Guide to Pharmacology1375UniProtKBP23219UniProt AccessionPGH1_HUMAN
synonyms:1.14.99.1COX-1COX1Cyclooxygenase-1PGH synthase 1PGHS-1PHS 1Prostaglandin H2 synthase 1Prostaglandin-endoperoxide synthase 1
amino-acid-sequence:>lcl|BSEQ0036935|Prostaglandin G/H synthase 1 MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL
gene-sequence:>lcl|BSEQ0021254|Prostaglandin G/H synthase 1 (PTGS1) ATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCCTGCTCCCGCCGCTCCCC GTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC CAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC ACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA CTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG TTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCGCCTGGTACTCACAGTGCGCTCC AACCTTATCCCCAGTCCCCCCACCTACAACTCAGCACATGACTACATCAGCTGGGAGTCT TTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA CCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC CTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT GCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC AAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG TATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG TACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC CAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT GCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC ACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC AAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT GACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCATGGAGTTC AACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG TACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC CTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC CACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG CCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC GTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG GAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT ATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT CCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG GCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT GTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA
pfams:PF03098An_peroxidasePF00008EGF
go-classifiers:componentcytoplasmcomponentendoplasmic reticulum membranecomponentextracellular exosomecomponentGolgi apparatuscomponentintracellular membrane-bounded organellecomponentnuclear envelopecomponentnucleuscomponentphotoreceptor outer segmentfunctiondioxygenase activityfunctionheme bindingfunctionlipid bindingfunctionmetal ion bindingfunctionperoxidase activityfunctionprostaglandin-endoperoxide synthase activityprocessagingprocessarachidonic acid metabolic processprocesscyclooxygenase pathwayprocessinflammatory responseprocesslearningprocesslipid metabolic processprocessmaintenance of blood-brain barrierprocessmemoryprocessnegative regulation of epinephrine secretionprocessnegative regulation of norepinephrine secretionprocesspositive regulation of smooth muscle contractionprocesspositive regulation of vasoconstrictionprocessprostaglandin biosynthetic processprocessregulation of blood pressureprocessregulation of cell proliferationprocessresponse to corticosteroneprocessresponse to fatty acidprocessresponse to organonitrogen compoundprocessresponse to oxidative stressprocesssensory perception of painprocesssmall molecule metabolic processprocessxenobiotic metabolic process
id:BE0000248
name:Arachidonate 5-lipoxygenase
organism:Humans
action:inhibitor
Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82.
Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51.
Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2.
known-action:yes
name:Arachidonate 5-lipoxygenase
general-function:Iron ion binding
specific-function:Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
gene-name:ALOX5
locus:10q11.2
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:5.54
molecular-weight:77982.595
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:435GenAtlasALOX5GenBank Gene DatabaseJ03600GenBank Protein Database187193Guide to Pharmacology1385UniProtKBP09917UniProt AccessionLOX5_HUMAN
synonyms:1.13.11.345-LOLOG5
amino-acid-sequence:>lcl|BSEQ0036979|Arachidonate 5-lipoxygenase MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDE ELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLA RDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVL NYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNG CNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDP CTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDF HVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECG LFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWE AIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYL TVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCW HLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPY YYLSPDRIPNSVAI
gene-sequence:>lcl|BSEQ0010032|Arachidonate 5-lipoxygenase (ALOX5) ATGCCCTCCTACACGGTCACCGTGGCCACTGGCAGCCAGTGGTTCGCCGGCACTGACGAC TACATCTACCTCAGCCTCGTGGGCTCGGCGGGCTGCAGCGAGAAGCACCTGCTGGACAAG CCCTTCTACAACGACTTCGAGCGTGGCGCGGTGGATTCATACGACGTGACTGTGGACGAG GAACTGGGCGAGATCCAGCTGGTCAGAATCGAGAAGCGCAAGTACTGGCTGAATGACGAC TGGTACCTGAAGTACATCACGCTGAAGACGCCCCACGGGGACTACATCGAGTTCCCCTGC TACCGCTGGATCACCGGCGATGTCGAGGTTGTCCTGAGGGATGGACGCGCAAAGTTGGCC CGAGATGACCAAATTCACATTCTCAAGCAACACCGACGTAAAGAACTGGAAACACGGCAA AAACAATATCGATGGATGGAGTGGAACCCTGGCTTCCCCTTGAGCATCGATGCCAAATGC CACAAGGATTTACCCCGTGATATCCAGTTTGATAGTGAAAAAGGAGTGGACTTTGTTCTG AATTACTCCAAAGCGATGGAGAACCTGTTCATCAACCGCTTCATGCACATGTTCCAGTCT TCTTGGAATGACTTCGCCGACTTTGAGAAAATCTTTGTCAAGATCAGCAACACTATTTCT GAGCGGGTCATGAATCACTGGCAGGAAGACCTGATGTTTGGCTACCAGTTCCTGAATGGC TGCAACCCTGTGTTGATCCGGCGCTGCACAGAGCTGCCCGAGAAGCTCCCGGTGACCACG GAGATGGTAGAGTGCAGCCTGGAGCGGCAGCTCAGCTTGGAGCAGGAGGTCCAGCAAGGG AACATTTTCATCGTGGACTTTGAGCTGCTGGATGGCATCGATGCCAACAAAACAGACCCC TGCACACTCCAGTTCCTGGCCGCTCCCATCTGCTTGCTGTATAAGAACCTGGCCAACAAG ATTGTCCCCATTGCCATCCAGCTCAACCAAATCCCGGGAGATGAGAACCCTATTTTCCTC CCTTCGGATGCAAAATACGACTGGCTTTTGGCCAAAATCTGGGTGCGTTCCAGTGACTTC CACGTCCACCAGACCATCACCCACCTTCTGCGAACACATCTGGTGTCTGAGGTTTTTGGC ATTGCAATGTACCGCCAGCTGCCTGCTGTGCACCCCATTTTCAAGCTGCTGGTGGCACAC GTGAGATTCACCATTGCAATCAACACCAAGGCCCGTGAGCAGCTCATCTGCGAGTGTGGC CTCTTTGACAAGGCCAACGCCACAGGGGGCGGTGGGCACGTGCAGATGGTGCAGAGGGCC ATGAAGGACCTGACCTATGCCTCCCTGTGCTTTCCCGAGGCCATCAAGGCCCGGGGCATG GAGAGCAAAGAAGACATCCCCTACTACTTCTACCGGGACGACGGGCTCCTGGTGTGGGAA GCCATCAGGACGTTCACGGCCGAGGTGGTAGACATCTACTACGAGGGCGACCAGGTGGTG GAGGAGGACCCGGAGCTGCAGGACTTCGTGAACGATGTCTACGTGTACGGCATGCGGGGC CGCAAGTCCTCAGGCTTCCCCAAGTCGGTCAAGAGCCGGGAGCAGCTGTCGGAGTACCTG ACCGTGGTGATCTTCACCGCCTCCGCCCAGCACGCCGCGGTCAACTTCGGCCAGTACGAC TGGTGCTCCTGGATCCCCAATGCGCCCCCAACCATGCGAGCCCCGCCACCGACTGCCAAG GGCGTGGTGACCATTGAGCAGATCGTGGACACGCTGCCCGACCGCGGCCGCTCCTGCTGG CATCTGGGTGCAGTGTGGGCGCTGAGCCAGTTCCAGGAAAACGAGCTGTTCCTGGGCATG TACCCAGAAGAGCATTTTATCGAGAAGCCTGTGAAGGAAGCCATGGCCCGATTCCGCAAG AACCTCGAGGCCATTGTCAGCGTGATTGCTGAGCGCAACAAGAAGAAGCAGCTGCCATAT TACTACTTGTCCCCAGACCGGATTCCGAACAGTGTGGCCATCTGA
pfams:PF01477PLATPF00305Lipoxygenase
go-classifiers:componentcytosolcomponentdendritecomponentextracellular spacecomponentnuclear envelopecomponentnuclear envelope lumencomponentnuclear matrixcomponentnuclear membranecomponentsarcolemmafunctionarachidonate 5-lipoxygenase activityfunctioniron ion bindingprocessacute inflammatory responseprocessarachidonic acid metabolic processprocessleukotriene biosynthetic processprocessleukotriene metabolic processprocessleukotriene production involved in inflammatory responseprocesslipoxin metabolic processprocesslipoxygenase pathwayprocesspositive regulation of vasoconstrictionprocessresponse to hyperoxiaprocessresponse to nutrientprocesssensory perception of painprocesssmall molecule metabolic process
id:BE0000215
name:Peroxisome proliferator-activated receptor gamma
organism:Humans
action:agonist
Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11.
Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9.
Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12.
Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9.
known-action:yes
name:Peroxisome proliferator-activated receptor gamma
general-function:Zinc ion binding
specific-function:Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).
gene-name:PPARG
locus:3p25
cellular-location:Nucleus
transmembrane-regions:
signal-regions:
theoretical-pi:5.77
molecular-weight:57619.58
chromosome-location:3
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:9236GenAtlasPPARGGenBank Gene DatabaseU79012GenBank Protein Database1711117IUPHAR595Guide to Pharmacology595UniProtKBP37231UniProt AccessionPPARG_HUMAN
synonyms:NR1C3Nuclear receptor subfamily 1 group C member 3PPAR-gamma
amino-acid-sequence:>lcl|BSEQ0000429|Peroxisome proliferator-activated receptor gamma MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSF DIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKT QLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNC RIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLR ALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQE QSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLAS LMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVII LSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQL LQVIKKTETDMSLHPLLQEIYKDLY
gene-sequence:>lcl|BSEQ0021642|Peroxisome proliferator-activated receptor gamma (PPARG) ATGACCATGGTTGACACAGAGATGCCATTCTGGCCCACCAACTTTGGGATCAGCTCCGTG GATCTCTCCGTAATGGAAGACCACTCCCACTCCTTTGATATCAAGCCCTTCACTACTGTT GACTTCTCCAGCATTTCTACTCCACATTACGAAGACATTCCATTCACAAGAACAGATCCA GTGGTTGCAGATTACAAGTATGACCTGAAACTTCAAGAGTACCAAAGTGCAATCAAAGTG GAGCCTGCATCTCCACCTTATTATTCTGAGAAGACTCAGCTCTACAATAAGCCTCATGAA GAGCCTTCCAACTCCCTCATGGCAATTGAATGTCGTGTCTGTGGAGATAAAGCTTCTGGA TTTCACTATGGAGTTCATGCTTGTGAAGGATGCAAGGGTTTCTTCCGGAGAACAATCAGA TTGAAGCTTATCTATGACAGATGTGATCTTAACTGTCGGATCCACAAAAAAAGTAGAAAT AAATGTCAGTACTGTCGGTTTCAGAAATGCCTTGCAGTGGGGATGTCTCATAATGCCATC AGGTTTGGGCGGATGCCACAGGCCGAGAAGGAGAAGCTGTTGGCGGAGATCTCCAGTGAT ATCGACCAGCTGAATCCAGAGTCCGCTGACCTCCGGGCCCTGGCAAAACATTTGTATGAC TCATACATAAAGTCCTTCCCGCTGACCAAAGCAAAGGCGAGGGCGATCTTGACAGGAAAG ACAACAGACAAATCACCATTCGTTATCTATGACATGAATTCCTTAATGATGGGAGAAGAT AAAATCAAGTTCAAACACATCACCCCCCTGCAGGAGCAGAGCAAAGAGGTGGCCATCCGC ATCTTTCAGGGCTGCCAGTTTCGCTCCGTGGAGGCTGTGCAGGAGATCACAGAGTATGCC AAAAGCATTCCTGGTTTTGTAAATCTTGACTTGAACGACCAAGTAACTCTCCTCAAATAT GGAGTCCACGAGATCATTTACACAATGCTGGCCTCCTTGATGAATAAAGATGGGGTTCTC ATATCCGAGGGCCAAGGCTTCATGACAAGGGAGTTTCTAAAGAGCCTGCGAAAGCCTTTT GGTGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTGAAGTTCAATGCACTGGAATTAGAT GACAGCGACTTGGCAATATTTATTGCTGTCATTATTCTCAGTGGAGACCGCCCAGGTTTG CTGAATGTGAAGCCCATTGAAGACATTCAAGACAACCTGCTACAAGCCCTGGAGCTCCAG CTGAAGCTGAACCACCCTGAGTCCTCACAGCTGTTTGCCAAGCTGCTCCAGAAAATGACA GACCTCAGACAGATTGTCACGGAACACGTGCAGCTACTGCAGGTGATCAAGAAGACGGAG ACAGACATGAGTCTTCACCCGCTCCTGCAGGAGATCTACAAGGACTTGTACTAG
pfams:PF00104Hormone_recepPF00105zf-C4PF12577PPARgamma_N
go-classifiers:componentcytosolcomponentGolgi apparatuscomponentintracellular membrane-bounded organellecomponentnucleoplasmcomponentnucleuscomponentperinuclear region of cytoplasmcomponentRNA polymerase II transcription factor complexfunctionactivating transcription factor bindingfunctionalpha-actinin bindingfunctionarachidonic acid bindingfunctionchromatin bindingfunctioncore promoter sequence-specific DNA bindingfunctionDNA bindingfunctiondrug bindingfunctionenzyme bindingfunctionligand-dependent nuclear receptor transcription coactivator activityfunctionprostaglandin receptor activityfunctionretinoid X receptor bindingfunctionRNA polymerase II regulatory region DNA bindingfunctionRNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA bindingfunctionsteroid hormone receptor activityfunctiontranscription factor activity, sequence-specific DNA bindingfunctiontranscription regulatory region DNA bindingfunctiontranscriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific bindingfunctionzinc ion bindingprocessactivation of cysteine-type endopeptidase activity involved in apoptotic processprocessbrown fat cell differentiationprocesscell fate commitmentprocesscell maturationprocesscellular response to hyperoxiaprocesscellular response to insulin stimulusprocesscellular response to lithium ionprocesscellular response to prostaglandin E stimulusprocesscellular response to retinoic acidprocesscellular response to vitamin Eprocessdiet induced thermogenesisprocessepithelial cell differentiationprocessfatty acid oxidationprocessG-protein coupled receptor signaling pathwayprocessgene expressionprocessglucose homeostasisprocessheart developmentprocessinnate immune responseprocesslipid homeostasisprocesslipid metabolic processprocesslipoprotein transportprocesslong-chain fatty acid transportprocesslow-density lipoprotein particle receptor biosynthetic processprocessmonocyte differentiationprocessnegative regulation of acute inflammatory responseprocessnegative regulation of cell growthprocessnegative regulation of cholesterol storageprocessnegative regulation of collagen biosynthetic processprocessnegative regulation of interferon-gamma-mediated signaling pathwayprocessnegative regulation of macrophage derived foam cell differentiationprocessnegative regulation of pancreatic stellate cell proliferationprocessnegative regulation of receptor biosynthetic processprocessnegative regulation of sequestering of triglycerideprocessnegative regulation of smooth muscle cell proliferationprocessnegative regulation of telomerase activityprocessnegative regulation of transcription from RNA polymerase II promoterprocessnegative regulation of transcription, DNA-templatedprocessorgan regenerationprocessperoxisome proliferator activated receptor signaling pathwayprocessplacenta developmentprocesspositive regulation of fat cell differentiationprocesspositive regulation of fatty acid oxidationprocesspositive regulation of oligodendrocyte differentiationprocesspositive regulation of phagocytosis, engulfmentprocesspositive regulation of sequence-specific DNA binding transcription factor activityprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of transcription, DNA-templatedprocessregulation of blood pressureprocessregulation of cholesterol transporter activityprocessregulation of circadian rhythmprocessregulation of transcription involved in cell fate commitmentprocessresponse to caffeineprocessresponse to coldprocessresponse to diureticprocessresponse to estrogenprocessresponse to immobilization stressprocessresponse to lipidprocessresponse to low-density lipoprotein particleprocessresponse to mechanical stimulusprocessresponse to metforminprocessresponse to nutrientprocessresponse to retinoic acidprocessresponse to starvationprocessresponse to vitamin Aprocessrhythmic processprocesssignal transductionprocesstranscription initiation from RNA polymerase II promoterprocesswhite fat cell differentiation
id:BE0004655
name:Inhibitor of nuclear factor kappa-B kinase subunit alpha
organism:Humans
action:inhibitor
Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7.
Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.
Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18.
known-action:unknown
name:Inhibitor of nuclear factor kappa-B kinase subunit alpha
general-function:Scaffold protein binding
specific-function:Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor (PubMed:15084260).
gene-name:CHUK
locus:
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:
molecular-weight:84638.88
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1974Guide to Pharmacology1989UniProtKBO15111UniProt AccessionIKKA_HUMAN
synonyms:2.7.11.10Conserved helix-loop-helix ubiquitous kinaseI-kappa-B kinase 1I-kappa-B kinase alphaIKK1IKKANFKBIKANuclear factor NF-kappa-B inhibitor kinase alphaTCF-16TCF16Transcription factor 16
amino-acid-sequence:>lcl|BSEQ0013242|Inhibitor of nuclear factor kappa-B kinase subunit alpha MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCH EIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQ ILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGSLCTS FVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPK CIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRC FVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGI SLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPI IQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKL EFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAE IMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRV LKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQ SSARSLVGSSLEGAVTPQTSAWLPPTSAEHDHSLSCVVTPQDGETSAQMIEENLNCLGHL STIIHEANEEQGNSMMNLDWSWLTE
gene-sequence:>lcl|BSEQ0013243|Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) ATGGAGCGGCCCCCGGGGCTGCGGCCGGGCGCGGGCGGGCCCTGGGAGATGCGGGAGCGG CTGGGCACCGGCGGCTTCGGGAACGTCTGTCTGTACCAGCATCGGGAACTTGATCTCAAA ATAGCAATTAAGTCTTGTCGCCTAGAGCTAAGTACCAAAAACAGAGAACGATGGTGCCAT GAAATCCAGATTATGAAGAAGTTGAACCATGCCAATGTTGTAAAGGCCTGTGATGTTCCT GAAGAATTGAATATTTTGATTCATGATGTGCCTCTTCTAGCAATGGAATACTGTTCTGGA GGAGATCTCCGAAAGCTGCTCAACAAACCAGAAAATTGTTGTGGACTTAAAGAAAGCCAG ATACTTTCTTTACTAAGTGATATAGGGTCTGGGATTCGATATTTGCATGAAAACAAAATT ATACATCGAGATCTAAAACCTGAAAACATAGTTCTTCAGGATGTTGGTGGAAAGATAATA CATAAAATAATTGATCTGGGATATGCCAAAGATGTTGATCAAGGAAGTCTGTGTACATCT TTTGTGGGAACACTGCAGTATCTGGCCCCAGAGCTCTTTGAGAATAAGCCTTACACAGCC ACTGTTGATTATTGGAGCTTTGGGACCATGGTATTTGAATGTATTGCTGGATATAGGCCT TTTTTGCATCATCTGCAGCCATTTACCTGGCATGAGAAGATTAAGAAGAAGGATCCAAAG TGTATATTTGCATGTGAAGAGATGTCAGGAGAAGTTCGGTTTAGTAGCCATTTACCTCAA CCAAATAGCCTTTGTAGTTTAGTAGTAGAACCCATGGAAAACTGGCTACAGTTGATGTTG AATTGGGACCCTCAGCAGAGAGGAGGACCTGTTGACCTTACTTTGAAGCAGCCAAGATGT TTTGTATTAATGGATCACATTTTGAATTTGAAGATAGTACACATCCTAAATATGACTTCT GCAAAGATAATTTCTTTTCTGTTACCACCTGATGAAAGTCTTCATTCACTACAGTCTCGT ATTGAGCGTGAAACTGGAATAAATACTGGTTCTCAAGAACTTCTTTCAGAGACAGGAATT TCTCTGGATCCTCGGAAACCAGCCTCTCAATGTGTTCTAGATGGAGTTAGAGGCTGTGAT AGCTATATGGTTTATTTGTTTGATAAAAGTAAAACTGTATATGAAGGGCCATTTGCTTCC AGAAGTTTATCTGATTGTGTAAATTATATTGTACAGGACAGCAAAATACAGCTTCCAATT ATACAGCTGCGTAAAGTGTGGGCTGAAGCAGTGCACTATGTGTCTGGACTAAAAGAAGAC TATAGCAGGCTCTTTCAGGGACAAAGGGCAGCAATGTTAAGTCTTCTTAGATATAATGCT AACTTAACAAAAATGAAGAACACTTTGATCTCAGCATCACAACAACTGAAAGCTAAATTG GAGTTTTTTCACAAAAGCATTCAGCTTGACTTGGAGAGATACAGCGAGCAGATGACGTAT GGGATATCTTCAGAAAAAATGCTAAAAGCATGGAAAGAAATGGAAGAAAAGGCCATCCAC TATGCTGAGGTTGGTGTCATTGGATACCTGGAGGATCAGATTATGTCTTTGCATGCTGAA ATCATGGAGCTACAGAAGAGCCCCTATGGAAGACGTCAGGGAGACTTGATGGAATCTCTG GAACAGCGTGCCATTGATCTATATAAGCAGTTAAAACACAGACCTTCAGATCACTCCTAC AGTGACAGCACAGAGATGGTGAAAATCATTGTGCACACTGTGCAGAGTCAGGACCGTGTG CTCAAGGAGCTGTTTGGTCATTTGAGCAAGTTGTTGGGCTGTAAGCAGAAGATTATTGAT CTACTCCCTAAGGTGGAAGTGGCCCTCAGTAATATCAAAGAAGCTGACAATACTGTCATG TTCATGCAGGGAAAAAGGCAGAAAGAAATATGGCATCTCCTTAAAATTGCCTGTACACAG AGTTCTGCCCGGTCCCTTGTAGGATCCAGTCTAGAAGGTGCAGTAACCCCTCAGACATCA GCATGGCTGCCCCCGACTTCAGCAGAACATGATCATTCTCTGTCATGTGTGGTAACTCCT CAAGATGGGGAGACTTCAGCACAAATGATAGAAGAAAATTTGAACTGCCTTGGCCATTTA AGCACTATTATTCATGAGGCAAATGAGGAACAGGGCAATAGTATGATGAATCTTGATTGG AGTTGGTTAACAGAATGA
pfams:PF00069PkinasePF12179IKKbetaNEMObind
go-classifiers:componentCD40 receptor complexcomponentcytoplasmcomponentcytoplasmic side of plasma membranecomponentcytosolcomponentIkappaB kinase complexcomponentintracellular membrane-bounded organellecomponentnucleoplasmfunctionATP bindingfunctionIkappaB kinase activityfunctionprotein heterodimerization activityfunctionprotein homodimerization activityfunctionprotein kinase activityfunctionscaffold protein bindingprocessanatomical structure morphogenesisprocesscell surface receptor signaling pathwayprocesscellular response to tumor necrosis factorprocessepidermal growth factor receptor signaling pathwayprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessI-kappaB kinase/NF-kappaB signalingprocessI-kappaB phosphorylationprocessimmune responseprocessinflammatory responseprocessinnate immune responseprocesslactationprocessmammary gland alveolus developmentprocessmammary gland epithelial cell proliferationprocessmorphogenesis of an epithelial sheetprocessMyD88-dependent toll-like receptor signaling pathwayprocessMyD88-independent toll-like receptor signaling pathwayprocessneurotrophin TRK receptor signaling pathwayprocessNIK/NF-kappaB signalingprocessnucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayprocessnucleotide-binding oligomerization domain containing signaling pathwayprocessodontogenesis of dentin-containing toothprocessosteoclast differentiationprocessphosphatidylinositol-mediated signalingprocesspositive regulation of I-kappaB kinase/NF-kappaB signalingprocesspositive regulation of NF-kappaB transcription factor activityprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of type I interferon productionprocessprotein phosphorylationprocessregulation of tumor necrosis factor-mediated signaling pathwayprocessresponse to acetateprocessresponse to amino acidprocessresponse to drugprocessresponse to hydroperoxideprocessresponse to lipopolysaccharideprocessresponse to muscle stretchprocessresponse to toxic substanceprocessresponse to virusprocessRho protein signal transductionprocessskeletal muscle contractionprocessstimulatory C-type lectin receptor signaling pathwayprocessstress-activated MAPK cascadeprocessstriated muscle cell differentiationprocessT cell receptor signaling pathwayprocesstoll-like receptor 10 signaling pathwayprocesstoll-like receptor 2 signaling pathwayprocesstoll-like receptor 3 signaling pathwayprocesstoll-like receptor 4 signaling pathwayprocesstoll-like receptor 5 signaling pathwayprocesstoll-like receptor 9 signaling pathwayprocesstoll-like receptor signaling pathwayprocesstoll-like receptor TLR1processtoll-like receptor TLR6processTRIF-dependent toll-like receptor signaling pathwayprocesstumor necrosis factor-mediated signaling pathway
id:BE0001154
name:Inhibitor of nuclear factor kappa-B kinase subunit beta
organism:Humans
action:inhibitor
Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7.
Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.
Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18.
known-action:unknown
name:Inhibitor of nuclear factor kappa-B kinase subunit beta
general-function:Scaffold protein binding
specific-function:Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.
gene-name:IKBKB
locus:8p11.2
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:5.53
molecular-weight:86563.245
chromosome-location:8
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5960GenAtlasIKBKBGenBank Gene DatabaseAF029684GenBank Protein Database2599558Guide to Pharmacology2039UniProtKBO14920UniProt AccessionIKKB_HUMAN
synonyms:2.7.11.10I-kappa-B kinase 2I-kappa-B-kinase betaIKK2IKKBNFKBIKBNuclear factor NF-kappa-B inhibitor kinase beta
amino-acid-sequence:>lcl|BSEQ0002295|Inhibitor of nuclear factor kappa-B kinase subunit beta MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCL EIQIMRRLTHPNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREG AILTLLSDIASALRYLHENRIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGSLCT SFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQPVQWHSKVRQKSE VDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCF KALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLA LIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRN LAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLK AKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMAL QTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQS FEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKI ACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLE NAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS
gene-sequence:>lcl|BSEQ0010805|Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) ATGTTTTCAGGGGGGTGTCATAGCCCCGGGTTTGGCCGCCCCAGCCCCGCCTTCCCCGCC CCGGGGAGCCCGCCCCCTGCCCCGCGTCCCTGCCGACAGGAAACAGGTGAGCAGATTGCC ATCAAGCAGTGCCGGCAGGAGCTCAGCCCCCGGAACCGAGAGCGGTGGTGCCTGGAGATC CAGATCATGAGAAGGCTGACCCACCCCAATGTGGTGGCTGCCCGAGATGTCCCTGAGGGG ATGCAGAACTTGGCGCCCAATGACCTGCCCCTGCTGGCCATGGAGTACTGCCAAGGAGGA GATCTCCGGAAGTACCTGAACCAGTTTGAGAACTGCTGTGGTCTGCGGGAAGGTGCCATC CTCACCTTGCTGAGTGACATTGCCTCTGCGCTTAGATACCTTCATGAAAACAGAATCATC CATCGGGATCTAAAGCCAGAAAACATCGTCCTGCAGCAAGGAGAACAGAGGTTAATACAC AAAATTATTGACCTAGGATATGCCAAGGAGCTGGATCAGGGCAGTCTTTGCACATCATTC GTGGGGACCCTGCAGTACCTGGCCCCAGAGCTACTGGAGCAGCAGAAGTACACAGTGACC GTCGACTACTGGAGCTTCGGCACCCTGGCCTTTGAGTGCATCACGGGCTTCCGGCCCTTC CTCCCCAACTGGCAGCCCGTGCAGTGGCATTCAAAAGTGCGGCAGAAGAGTGAGGTGGAC ATTGTTGTTAGCGAAGACTTGAATGGAACGGTGAAGTTTTCAAGCTCTTTACCCTACCCC AATAATCTTAACAGTGTCCTGGCTGAGCGACTGGAGAAGTGGCTGCAACTGATGCTGATG TGGCACCCCCGACAGAGGGGCACGGATCCCACGTATGGGCCCAATGGCTGCTTCAAGGCC CTGGATGACATCTTAAACTTAAAGCTGGTTCATATCTTGAACATGGTCACGGGCACCATC CACACCTACCCTGTGACAGAGGATGAGAGTCTGCAGAGCTTGAAGGCCAGAATCCAACAG GACACGGGCATCCCAGAGGAGGACCAGGAGCTGCTGCAGGAAGCGGGCCTGGCGTTGATC CCCGATAAGCCTGCCACTCAGTGTATTTCAGACGGCAAGTTAAATGAGGGCCACACATTG GACATGGATCTTGTTTTTCTCTTTGACAACAGTAAAATCACCTATGAGACTCAGATCTCC CCACGGCCCCAACCTGAAAGTGTCAGCTGTATCCTTCAAGAGCCCAAGAGGAATCTCGCC TTCTTCCAGCTGAGGAAGGTGTGGGGCCAGGTCTGGCACAGCATCCAGACCCTGAAGGAA GATTGCAACCGGCTGCAGCAGGGACAGCGAGCCGCCATGATGAATCTCCTCCGAAACAAC AGCTGCCTCTCCAAAATGAAGAATTCCATGGCTTCCATGTCTCAGCAGCTCAAGGCCAAG TTGGATTTCTTCAAAACCAGCATCCAGATTGACCTGGAGAAGTACAGCGAGCAAACCGAG TTTGGGATCACATCAGATAAACTGCTGCTGGCCTGGAGGGAAATGGAGCAGGCTGTGGAG CTCTGTGGGCGGGAGAACGAAGTGAAACTCCTGGTAGAACGGATGATGGCTCTGCAGACC GACATTGTGGACTTACAGAGGAGCCCCATGGGCCGGAAGCAGGGGGGAACGCTGGACGAC CTAGAGGAGCAAGCAAGGGAGCTGTACAGGAGACTAAGGGAAAAACCTCGAGACCAGCGA ACTGAGGGTGACAGTCAGGAAATGGTACGGCTGCTGCTTCAGGCAATTCAGAGCTTCGAG AAGAAAGTGCGAGTGATCTATACGCAGCTCAGTAAAACTGTGGTTTGCAAGCAGAAGGCG CTGGAACTGTTGCCCAAGGTGGAAGAGGTGGTGAGCTTAATGAATGAGGATGAGAAGACT GTTGTCCGGCTGCAGGAGAAGCGGCAGAAGGAGCTCTGGAATCTCCTGAAGATTGCTTGT AGCAAGGTCCGTGGTCCTGTCAGTGGAAGCCCGGATAGCATGAATGCCTCTCGACTTAGC CAGCCTGGGCAGCTGATGTCTCAGCCCTCCACGGCCTCCAACAGCTTACCTGAGCCAGCC AAGAAGAGTGAAGAACTGGTGGCTGAAGCACATAACCTCTGCACCCTGCTAGAAAATGCC ATACAGGACACTGTGAGGGAACAAGACCAGAGTTTCACGGCCCTAGACTGGAGCTGGTTA CAGACGGAAGAAGAAGAGCACAGCTGCCTGGAGCAGGCCTCATGA
pfams:PF00069PkinasePF12179IKKbetaNEMObind
go-classifiers:componentCD40 receptor complexcomponentcytoplasmcomponentcytoplasmic side of plasma membranecomponentcytosolcomponentIkappaB kinase complexcomponentmembrane raftcomponentnucleusfunctionATP bindingfunctionIkappaB kinase activityfunctionprotein heterodimerization activityfunctionprotein homodimerization activityfunctionprotein kinase activityfunctionprotein kinase bindingfunctionprotein serine/threonine kinase activityfunctionscaffold protein bindingprocessB cell homeostasisprocesscell surface receptor signaling pathwayprocesscellular response to tumor necrosis factorprocesscortical actin cytoskeleton organizationprocessestablishment of protein localization to plasma membraneprocessFc-epsilon receptor signaling pathwayprocessI-kappaB kinase/NF-kappaB signalingprocessI-kappaB phosphorylationprocessinflammatory responseprocessinnate immune responseprocessinterleukin-1-mediated signaling pathwayprocessMyD88-dependent toll-like receptor signaling pathwayprocessMyD88-independent toll-like receptor signaling pathwayprocessnegative regulation of apoptotic processprocessnegative regulation of bicellular tight junction assemblyprocessnegative regulation of myosin-light-chain-phosphatase activityprocessneuron projection developmentprocessneurotrophin TRK receptor signaling pathwayprocessnucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayprocessnucleotide-binding oligomerization domain containing signaling pathwayprocesspositive regulation of cation channel activityprocesspositive regulation of cell proliferationprocesspositive regulation of I-kappaB kinase/NF-kappaB signalingprocesspositive regulation of neuron deathprocesspositive regulation of NF-kappaB transcription factor activityprocesspositive regulation of sodium ion transportprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of transcription, DNA-templatedprocesspositive regulation of type I interferon productionprocessprotein phosphorylationprocessregulation of establishment of endothelial barrierprocessregulation of phosphorylationprocessregulation of tumor necrosis factor-mediated signaling pathwayprocessresponse to drugprocessresponse to fatty acidprocessresponse to toxic substanceprocessresponse to virusprocessserine phosphorylation of STAT proteinprocessskeletal muscle contractionprocessstimulatory C-type lectin receptor signaling pathwayprocessstress-activated MAPK cascadeprocessT cell receptor signaling pathwayprocesstoll-like receptor 10 signaling pathwayprocesstoll-like receptor 2 signaling pathwayprocesstoll-like receptor 3 signaling pathwayprocesstoll-like receptor 4 signaling pathwayprocesstoll-like receptor 5 signaling pathwayprocesstoll-like receptor 9 signaling pathwayprocesstoll-like receptor signaling pathwayprocesstoll-like receptor TLR1processtoll-like receptor TLR6processTRIF-dependent toll-like receptor signaling pathwayprocesstumor necrosis factor-mediated signaling pathway
id:BE0001075
name:Myeloperoxidase
organism:Humans
Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15.
known-action:unknown
name:Myeloperoxidase
general-function:Peroxidase activity
specific-function:Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
gene-name:MPO
locus:17q23.1
cellular-location:Lysosome
transmembrane-regions:
signal-regions:1-48
theoretical-pi:9.14
molecular-weight:83867.71
chromosome-location:17
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:7218GenAtlasMPOGenBank Gene DatabaseJ02694GenBank Protein Database189040Guide to Pharmacology2789UniProtKBP05164UniProt AccessionPERM_HUMAN
synonyms:1.11.2.2MPO
amino-acid-sequence:>lcl|BSEQ0002139|Myeloperoxidase MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS NSYPRDFVNCSTLPALNLASWREAS
gene-sequence:>lcl|BSEQ0016304|Myeloperoxidase (MPO) ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC TGGAGGGAAGCCTCCTAG
pfams:PF03098An_peroxidase
go-classifiers:componentazurophil granulecomponentextracellular exosomecomponentextracellular spacecomponentlysosomecomponentmitochondrioncomponentnucleuscomponentsecretory granulefunctionchromatin bindingfunctionheme bindingfunctionheparin bindingfunctionmetal ion bindingfunctionperoxidase activityprocessdefense responseprocessdefense response to fungusprocesshydrogen peroxide catabolic processprocesshypochlorous acid biosynthetic processprocesslow-density lipoprotein particle remodelingprocessnegative regulation of apoptotic processprocessnegative regulation of growth of symbiont in hostprocessoxidation-reduction processprocessremoval of superoxide radicalsprocessrespiratory burst involved in defense responseprocessresponse to oxidative stressprocessresponse to yeast
id:BE0004429
name:Arylamine N-acetyltransferase
organism:Mycobacterium tuberculosis
Tucker MA, Smith TJ: Acetylation of 5-aminosalicylate by hamster colon arylamine N-acetyltransferase. J Appl Toxicol. 1990 Feb;10(1):73-4.
known-action:unknown
name:Arylamine N-acetyltransferase
general-function:Catalyzes the transfer of the acetyl group from acetyl coenzyme A to the free amino group of arylamines and hydrazines (PubMed:18795795). Is able to utilize not only acetyl-CoA, but also n-propionyl-CoA and acetoacetyl-CoA as acyl donors, although at a lower rate (PubMed:19014350). As acetyl-CoA and propionyl-CoA are products of cholesterol catabolism and the nat gene is likely present in the same operon than genes involved in cholesterol degradation, this enzyme could have a role in the utilization and regulation of these CoA species (PubMed:19014350).
specific-function:Arylamine n-acetyltransferase activity
gene-name:nat
locus:
cellular-location:
transmembrane-regions:
signal-regions:
theoretical-pi:
molecular-weight:31028.88
chromosome-location:
organism:Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
external-identifiers:UniProtKBP9WJI5UniProt AccessionNAT_MYCTU
synonyms:2.3.1.5NATnhoAtbnat
amino-acid-sequence:>lcl|BSEQ0051280|Arylamine N-acetyltransferase MALDLTAYFDRINYRGATDPTLDVLQDLVTVHSRTIPFENLDPLLGVPVDDLSPQALADK LVLRRRGGYCFEHNGLMGYVLAELGYRVRRFAARVVWKLAPDAPLPPQTHTLLGVTFPGS GGCYLVDVGFGGQTPTSPLRLETGAVQPTTHEPYRLEDRVDGFVLQAMVRDTWQTLYEFT TQTRPQIDLKVASWYASTHPASKFVTGLTAAVITDDARWNLSGRDLAVHRAGGTEKIRLA DAAAVVDTLSERFGINVADIGERGALETRIDELLARQPGADAP
gene-sequence:>lcl|BSEQ0051281|Arylamine N-acetyltransferase (nat) ATGGCACTGGATCTGACCGCGTACTTCGATCGCATCAACTATCGCGGCGCTACCGATCCA ACCCTGGATGTTCTGCAGGATCTGGTGACCGTGCACAGTCGAACGATTCCGTTCGAGAAC CTCGACCCGCTGCTGGGGGTGCCGGTCGACGACCTCAGTCCACAGGCGCTGGCCGACAAG CTGGTACTTCGGCGCCGAGGCGGGTACTGCTTTGAGCACAACGGGCTGATGGGTTATGTG CTGGCCGAACTCGGCTATCGGGTGCGCCGATTCGCCGCCCGCGTCGTCTGGAAGCTCGCG CCGGACGCGCCCCTGCCGCCGCAGACGCACACCCTGCTGGGGGTCACGTTCCCCGGCTCG GGCGGATGCTATCTCGTCGACGTCGGATTCGGCGGCCAAACACCGACCTCACCGCTTCGC CTCGAAACCGGCGCCGTCCAGCCGACAACGCACGAACCTTATCGGCTCGAGGACCGCGTC GACGGCTTTGTCTTGCAGGCGATGGTCCGGGACACATGGCAGACACTGTACGAATTCACC ACCCAGACCCGCCCGCAGATCGATCTGAAAGTGGCCAGCTGGTACGCCTCAACACACCCG GCATCGAAGTTCGTCACGGGACTGACCGCCGCGGTGATCACCGACGACGCCCGGTGGAAC CTATCTGGCCGCGACCTTGCCGTTCACCGTGCCGGTGGTACCGAGAAGATCCGCCTTGCC GATGCGGCAGCGGTTGTCGACACCCTGAGCGAACGGTTCGGGATCAACGTGGCAGATATC GGCGAGCGCGGCGCGCTCGAGACGCGCATCGACGAGCTATTGGCTCGGCAGCCAGGAGCC GATGCGCCGTAA
pfams:PF00797Acetyltransf_2
go-classifiers:componentplasma membranefunctionarylamine N-acetyltransferase activityprocessmetabolic processprocessresponse to antibiotic
BE0003608Arylamine N-acetyltransferase 1HumanssubstrateF3010Mesalazine FDA Label//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/010/original/091640Orig1s000lbl.pdf?1548099366unknownArylamine N-acetyltransferase 1Arylamine n-acetyltransferase activityParticipates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.NAT18p23.1-p21.3Cytoplasm6.5133898.4458HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:7645GenBank Gene DatabaseD90041GenBank Protein Database219414UniProtKBP18440UniProt AccessionARY1_HUMAN2.3.1.5AAC1Arylamide acetylase 1MNATMonomorphic arylamine N-acetyltransferaseN-acetyltransferase type 1NAT-1>lcl|BSEQ0017156|Arylamine N-acetyltransferase 1 MDIEAYLERIGYKKSRNKLDLETLTDILQHQIRAVPFENLNIHCGDAMDLGLEAIFDQVV RRNRGGWCLQVNHLLYWALTTIGFETTMLGGYVYSTPAKKYSTGMIHLLLQVTIDGRNYI VDAGFGRSYQMWQPLELISGKDQPQVPCVFRLTEENGFWYLDQIRREQYIPNEEFLHSDL LEDSKYRKIYSFTLKPRTIEDFESMNTYLQTSPSSVFTSKSFCSLQTPDGVHCLVGFTLT HRRFNYKDNTDLIEFKTLSEEEIEKVLKNIFNISLQRKLVPKHGDRFFTI>lcl|BSEQ0017157|Arylamine N-acetyltransferase 1 (NAT1) ATGGACATTGAAGCATATCTTGAAAGAATTGGCTATAAGAAGTCTAGGAACAAATTGGAC TTGGAAACATTAACTGACATTCTTCAACACCAGATCCGAGCTGTTCCCTTTGAGAACCTT AACATCCATTGTGGGGATGCCATGGACTTAGGCTTAGAGGCCATTTTTGATCAAGTTGTG AGAAGAAATCGGGGTGGATGGTGTCTCCAGGTCAATCATCTTCTGTACTGGGCTCTGACC ACTATTGGTTTTGAGACCACGATGTTGGGAGGGTATGTTTACAGCACTCCAGCCAAAAAA TACAGCACTGGCATGATTCACCTTCTCCTGCAGGTGACCATTGATGGCAGGAACTACATT GTCGATGCTGGGTTTGGACGCTCATACCAGATGTGGCAGCCTCTGGAGTTAATTTCTGGG AAGGATCAGCCTCAGGTGCCTTGTGTCTTCCGTTTGACGGAAGAGAATGGATTCTGGTAT CTAGACCAAATCAGAAGGGAACAGTACATTCCAAATGAAGAATTTCTTCATTCTGATCTC CTAGAAGACAGCAAATACCGAAAAATCTACTCCTTTACTCTTAAGCCTCGAACAATTGAA GATTTTGAGTCTATGAATACATACCTGCAGACATCTCCATCATCTGTGTTTACTAGTAAA TCATTTTGTTCCTTGCAGACCCCAGATGGGGTTCACTGTTTGGTGGGCTTCACCCTCACC CATAGGAGATTCAATTATAAGGACAATACAGATCTAATAGAGTTCAAGACTCTGAGTGAG GAAGAAATAGAAAAAGTGCTGAAAAATATATTTAATATTTCCTTGCAGAGAAAGCTTGTG CCCAAACATGGTGATAGATTTTTTACTATTTAGPF00797Acetyltransf_2componentcytosolfunctionarylamine N-acetyltransferase activityprocesssmall molecule metabolic processprocessxenobiotic metabolic process
载体
运输工具
药物反应
reactions:1
left-element--drugbank-id:DB00244
left-element--name:Mesalazine
right-element--drugbank-id:DBMET00924
right-element--name:N-acetyl-5-ASA (Ac-5-ASA)
enzymes--drugbank-id:BE0003608
enzymes--name:Arylamine N-acetyltransferase 1
enzymes--uniprot-id:P18440
效应
不良反应